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ABSTRACT 
Since Darwin popularized the evolution theory in 1895, it has been completed and 
studied through the years. Starting in 1990s, evolution at molecular level has been used to 
discover functional molecules while studying the origin of functional molecules in nature 
by mimicing the natural selection process in laboratory. Along this line, my Ph.D. 
dissertation focuses on the in vitro selection of two important biomolecules, 
deoxynucleotide acid (DNA) and protein with binding properties.  
Chapter two focuses on in vitro selection of DNA. Aptamers are single-stranded 
nucleic acids that generated from a random pool and fold into stable three-dimensional 
structures with ligand binding sites that are complementary in shape and charge to a 
desired target. While aptamers have been selected to bind a wide range of targets, it is 
generally thought that these molecules are incapable of discriminating strongly alkaline 
proteins due to the attractive forces that govern oppositely charged polymers. By 
employing negative selection step to eliminate aptamers that bind with off-target through 
charge unselectively, an aptamer that binds with histone H4 protein with high specificity 
(>100 fold)was generated. 
Chapter four focuses on another functional molecule: protein. It is long believed 
that complex molecules with different function originated from simple progenitor 
proteins, but very little is known about this process. By employing a previously selected 
protein that binds and catalyzes ATP, which is the first and only protein that was evolved 
completely from random pool and has a uniqueα/β-fold protein scaffold, I fused random 
library to the C-terminus of this protein and evolved a multi-domain protein with decent 
properties. 
ii 
Also, in chapter 3, a unique bivalent molecule was generated by conjugating 
peptides that bind different sites on the protein with nucleic acids. By using the ligand 
interactions by nucleotide conjugates technique, off-the shelf peptide was transferred into 
high affinity protein capture reagents that mimic the recognition properties of natural 
antibodies. The designer synthetic antibody amplifies the binding affinity of the 
individual peptides by ∼1000-fold to bind Grb2 with a Kd of 2 nM, and functions with 
high selectivity in conventional pull-down assays from HeLa cell lysates. 
iii 
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Chapter 1 Development of In Vitro Selection 
 
1.1 Basic Principles of Darwinian Selection 
1.1.1 Principle of natural selection. Natural selection is a continuous process 
where biological properties become either more or less common in a population as result 
of differentiation in the reproduction rate causes by that particular property. The basic 
principle of natural selection is that the selection acts on the phenotype, which in nature 
would mostly be obersevable change in organisms, and any phenotype that results in a 
reproductive advantage will become more popular in the genotype of that population 
[1]
. 
(Figure 1.1a) 
The term “natural selection” was first popularized by Charles Darwin in the book 
On The Origin of Species, published in 1859, with intention to be compared with 
“artificial selection”, a process by which organisms with desirable traits are 
systematically favored for production 
[2]
. Natural selection is the key mechanism for 
evolution. However, evolution also includes other non-adaptive caused evolution such as 
gene flow and gene-drift 
[50]
.  
One of the most famous examples of natural selection is the change of color of 
pepper moth in United Kingdom 
[49]
. These moths exist in both dark and light colors 
while light color moths made the majority of population. But during the industrial 
revolution, trees that moths rested on were blackened by soot. The dark moths had more 
advantage in hiding themselves in the environment from the predator, thus the 
reproduction of dark moths made it become the majority of the moth population. The 
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clean air act in 1956, however, discolored the trees and the light moths became the main 
population again.  
When the natural selection is applied to molecular level, like deoxyribonucleic 
acid (DNA), ribonucleic acid (RNA) or protein, it can be referred to as molecular 
evolution. It was first developed to study thing such as species divergence, the evolution 
of protein functions and so on. Then in the 90s, researchers developed a way to mimic the 
evolution process in lab within test tubes to evolve functional molecules to fit for special 
needs by combining chemistry technique with molecular biology and evolution theory.  
This process is called in vitro selection. 
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Figure 1.1 The principle of Darwinian evolution. a) In natural evolution, after mutations 
occur in the population, those mutations that lead to higher reproduction rate will be 
enriched while the mutations that fail to do so will be eliminated from the population. b) 
In molecular evolution, a large pool of library with random molecules will go through 
certain selection pressure. Those molecules that fail to survive under the selection 
pressure will be eliminated while the survived molecules will be amplified and enriched 
through the selection. 
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1.1.2 Basic principle of in vitro selection. The concept of in vitro selection was 
firstly introduced to the field of molecular evolution by three different groups (Larry 
Gold, Gerald Joyce and Jack Szostak) 
[3] [4] [5]
 spontaneously in 1990. The principle of 
molecular evolution served as the key mechanism for in vitro selection, where genotype 
is represented by a sequence that can be amplified (which in most cases means being 
copied by polymerase), and phenotype is represented by the functional trials of the 
molecule, i.e. binding ATP or catalyze RNA cleavage 
[6]
.  
Similar to natural selection, the process starts with a large pool of random 
molecules, which in most cases are nucleic acids or polypeptides, and certain selection 
pressure would be applied to the random pool. Those molecules that survive from the 
selection pressure will be amplified. They will either become the starting point for the 
next round of selection or be sequenced for further analysis at the end of selection process 
[7] [8]
. (Figure 1b) The most important elements in the process of in vitro selection are that 
a pool containing enough variety of molecules; selection pressure necessary to eliminate 
undesired molecules; and ability to replicate selected molecules. The term “in vitro 
selection” is also known as systematic evolution of ligands by exponential enrichment [5] 
(SELEX). 
 5 
 
Figure 1.2 The principle of In vitro selection. a) In vitro selection of aptamers. Double 
stranded DNA pool is strand separated or transcribed into single strand DNA or RNA 
library and folded into aptamers pool with different secondary structures. Those aptamers 
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that bind with the target will be recovered and PCR amplified for the next round of 
selection. b) In vitro selection of polypeptides (Messenger RNA display is used as the 
representative here as the mechanisms for different polypeptides selection strategies are 
quite different from each other.). DNA library that codes the polypeptide sequence is 
transcribed and translated into polypeptides. The mRNA and polypeptide are linked 
together and reverse transcribed to avoid the enrichment of RNA aptamers. The mRNA-
cDNA-polypeptide fusion that binds with target will be recovered and amplified for the 
next round of selection. 
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1.2 History of in vitro selection 
1.2.1 Molecular evolution of nucleic acids. For nucleic acids like DNA or RNA, 
the molecules themselves serve as both the genotype and phenotype. More importantly, 
the invention of polymerase chain reaction 
[9]
 (PCR) made it possible for DNA to amplify 
in a rapid exponential pattern, and the isolation of reverse transcriptase 
[10] [11]
 made it 
easy to replicate RNA molecules in vitro as well (Figure 2a). Functional DNA and RNA 
molecules are single stranded and can fold into a stable three-dimensional structure with 
functional sites. The molecules being selected as affinity reagents to bind targets are 
referred to as ‘aptamers’. The name originated from the Latin word aptus, which means 
fit, and Greek word meros, which means part 
[5]
. Aptamers will be discussed with more 
details in the next session. 
Aside from aptamers, nucleic acids have also been evolved as catalysis such as 
RNA molecules that can cleaves single-stranded DNA or DNA molecules that can 
cleaves RNA with different possible metal dependent characteristics. The main difference 
between the evolution of nucleotide enzymes and aptamers is that because they have 
different selection pressures, during the selection step, instead of selecting molecules that 
can bind with targets, the molecules that can catalyze a certain reaction will survive 
[12]
. 
For example, if the goal of the evolution was to select molecules that can cleavage a 
certain DNA sequence, these molecules containing both the random region and the 
substrates were linked to a stationery support, normally a column. Those nucleic acid 
molecules that can cleave the substrate would cut themselves from the column and thus 
be amplified 
[13]
 (Figure 3). Those selected molecules with biocatalytical features are 
often referred to as ribozyme or deoxyribozyme. 
 8 
 
Figure 1.3 Selection scheme for isolation of DNAs that catalyze the co-factor dependent 
cleavage of a RNA phosphoester 
[13]
. Reprinted from Chemistry&Biology, 2(10), Breaker, 
R.R.; Joyce, G.F. A DNA enzyme with Mg
2+
-dependent RNA phosphoesterase activity, pg 
655-660, Copyright (1995), with permission from Elsevier. 
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1.2.2 Molecular evolution of peptide and proteins. For the evolution of 
polypeptides, the main difference is that the genotype is represented by the genetic 
information carried by the nucleic acid coding sequence while the phenotype is 
represented by the functions of the peptide chains (Figure 2b). It would be more difficult 
to apply the in vitro selection to these molecules, since up until now no methods have 
been developed to replicate polypeptides sequences directly. So how to connect the 
phenotype of the molecule with its genotype becomes the most important issue in 
polypeptide selection 
[14]
. To overcome this problem, two main in vitro selection methods 
have been developed for peptide and protein selection: ribosome display
 [15] 
and 
messenger RNA (mRNA) display 
[16]
. Another common evolution method for 
polypeptide is in vivo selection such as phage display 
[17]
, but that does not count as in 
vitro selection since cells were involved in the selection process. All these methods and 
their advantages and disadvantages will be discussed in details later. 
 
1.3 In Vitro Selection of Aptamers. 
1.3.1 Conventional selection strategy. The first two papers stating aptamer 
selection both employed the traditional selection strategy and chose RNA as the ligand
 [5] 
[6]
. The Gold group chose bacteriophage T4 DNA polymerase to be the target and the 
Szostak group selected aptamers against different dyes. The schemes for both selections 
were much similar with a random DNA pool containing T7 promoter as the starting point. 
The DNA pool was then transcribed to single stranded RNA pool and folded into various 
secondary structures. After incubation with the target for a certain amount of time, the 
unbound sequences would be washed off and the bound sequences would combine to a 
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stationary support (nitrocellulose membrane in the Gold paper and affinity column in the 
Szostak paper) together with the target. The selected sequences would be recovered by 
elution, reverse transcribed into DNA and amplified by PCR to reenter the next round 
selection (Figure 1.4a). The selection would carry along from round to round until the 
bound sequences stop enriching in the library. 
Following these two papers, this strategy becomes the most commonly used 
scheme for aptamer selection. In some cases, DNA aptamers were selected instead of 
RNA, which would make the selection process even more straightforward as no 
transcription or reverse transcription would be required 
[18]
. The PCR amplified DNA 
pool would be separated into single stranded DNA molecules, then folded and bound 
with target. The recovered bound fraction would be amplified directly via PCR and 
reenter the pool for the next round of selection. This strategy is simple, universal and can 
be applied to almost all kinds of different targets. Many renowned aptamers that serve as 
the standard for aptamer selection, such as ATP-binding aptamers 
[19] [20] 
and thrombin 
aptamers 
[21]
 were evolved with this strategy.  
However, there are several disadvantages of the conventional selection. One is 
that the targets are linked to a stationery support, which prevents the target from 
interacting with aptamers freely as in solution, and it can result in elimination of potential 
binding site 
[22]
. Another noticeable bias is that during the elution step, if one sequence 
bound to the target strongly, it would be hard to be washed off the column, which 
indicates that the kinetics bias against the best binders 
[23]
.  
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Figure 1.4 Conventional SELEX and CE SELEX. a) In conventional SELEX, targets are 
linked to a stationery support. Sequences that bind targets will be recovered by elution 
and PCR amplified. b) In CE SELEX, targets bind with sequences in solution. The bound 
sequences and unbound sequences have different mobility shift and can be separated by 
capillary electrophoresis. The bound sequences would be amplified directly afterwards. 
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Another disadvantage of traditional selection is that the whole process requires 
normally eight to twelve rounds of selection to generate an aptamer with decent binding 
ability (measured by dissociation constant, also known as Kd). A typical selection 
normally takes more than one month to finish 
[24]
. The Ellington group managed to 
shorten this process to three days by using a selection robot 
[25]
, but the robot is not 
available to all the research groups and it has not been widely proven to be effective. 
 
1.3.2 Capillary Electrophoresis SELEX. In 2004, a brand new strategy called 
capillary electrophoresis SELEX has been developed for aptamer selection 
[22]
. The basic 
principle of CE is that the mobility of certain molecule associates with its mass/charge 
ratio. When a molecule transports towards the electro with opposite charge, the higher 
mass/charge ratio is, the slower that molecule would move. So when aptamers bind with 
protein, a mobility shift would occur to separate bound sequences with unbound 
sequences. It has been applied to measure the Kd of aptamers by affinity capillary 
electrophoresis (ACE) 
[26]
. 
This selection strategy can come over the main issues with conventional beads-
selection mentioned above. At the selection step, when CE is applied to separate the 
bound and unbound sequences, which eliminates the stationery support; and no washing 
step would be required to recover bound sequences, which eliminates kinetically biased 
elution (Figure 4b). Also, a typical CE-SELEX requires only four rounds of selection and 
can be finished in two weeks time in most circumstances 
[22][24][27]
. 
The disadvantage of CE-SELEX is, however, it does not apply to all the targets. If 
binding a target does not provide the mobility shift that can be distinguished by the 
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instrument, the bound sequence cannot be separated and the selection cannot carry on. 
For example, ATP, which is a nucleoside triphosphate, has very similar mobility with 
DNA. But this disadvantage can be overcome by linking the target to a supplier molecule 
the can provide the shift required. In this case a negative selection must be included to 
avoid selecting aptamer against that certain supplier molecule.  
 
1.3.3 Other SELEX strategies. Besides these two most commonly used methods, 
there are several other aptamer selection strategies, such as microfluidic-based SELEX 
[28] 
[29]
, which is normally processed on a chip and serves as an advanced method to evolve 
aptamer rapidly and automatically. Other methods include atomic force microscope 
(AFM) based assay 
[30]
; surface Plasmon resonance (SPR) based assay 
[31]
 and 
electrophoretic mobility shift assays (EMSA) associated assay 
[32]
. However these 
methods have not been broadly used, which makes hard to evaluate these strategies. 
 
1.3.4 The application of aptamers. Comparing to antibodies, which is one of the 
most common affinity reagents existing in nature, aptamers have several advantages 
[33] 
[34]
. Aptamers are more thermal stable and can be reversibly denatured compared with 
protein, which often suffers irreversible denaturing under high temperature. The aptamers 
are non-immunogenic and normally non-toxic. The process of aptamers selections is 
normally in vitro, which means it does not require bacterial, virus or any kinds of cells 
while producing of antibodies needs animals. While antibodies are difficult to identify in 
terms of molecules that do not elicit strong immune response, aptamers can be selected 
against a much broader range of target, from big proteins to small ions. Aptamers can be 
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produced chemically with a readily scalable process and their characteristics remain 
stable and consistent from batch to batch. Through synthesis, it is possible to conjugate 
chemicals like fluorophores, quenchers and other functional groups to aptamers. 
Based on the advantages described above, aptamers are considered to be a useful 
alternative for antibodies in many biological and chemical applications 
[35]
. One common 
usage of aptamers is the identification element in biosensors. Those biosensors that are 
based on aptamers are referred to as aptasensors 
[36]
. There are several kinds of 
aptasensors, the most important of which are optical aptasensors (i.e. fluorescence based 
sensors); electrochemical aptasensors and mass sensitive aptasensors 
[37]
 (i.e. biosensors 
associated with SPR). Although these assays are still immature comparing with well-
developed immunoassays, they have been proved to be reliable methods for detection 
both in the basic research and biomedical diagnostics 
[37]
.  
Aptamers have also served as therapeutics 
[34] [38]
. In 2004, the approval of the first 
aptamer drug “Macugen” that treats age related macular degeneration by Food and Drug 
Administration (FDA) marks the breakthrough for aptamer technologies in therapeutic 
application. 
[35][39]
 Macugen binds with all isoforms of human vascular endothelial growth 
factor A (VEGFA) except for the smallest VEGF121. It was initially selected in a 2’-ribo 
purine/2’-fluoro pyrimidine transcript library and truncated to 27 nucleotides after 
selection 
[40]
. To increase nuclease rersistance, 12 out of 14 riboputines were replaced 
with 2’-O-methyl purines and 3’ terminus was capped with an inverted nucleotide to 
reduce 3’ exonuclease mediated degradation [41]. Once it binds with VEGF, macugen 
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inhibits the interaction between VEGF and its receptors VEGFR1 and VEGFR2. There 
are several other aptamers that enter the clinical trials to date 
[34]
.  
1.4 Selection of Peptides and Proteins 
Despite the many advantages of aptamers, proteins still serve as the main ligand 
choosing by nature. One important reason is that polypeptides have much more variety in 
the kinds of building blocks comparing with nucleic acids, which gives the ligand more 
freedom in forming different kinds of bonds with the target. Besides, polypeptide does 
not have nuclease cleavage issue, especially for applications in vivo, and the variety 
charge on the surface rather than highly negatively charge would make it easier to cross 
biological membrane if other factors are not taken into consideration. 
As mentioned previously, the most important issue in evolution of polypeptides is 
how to connect the phenotype and genotype together. In vivo strategies do so by placing 
the phenotype on the surface while keep the genotype inside the cell, and in vitro 
strategies do so by covalently or non-covalently conjugating the phenotype and genotype 
together 
[47]
. There are also other selection strategies such as in vitro 
compartmentalization 
[48]
, in which a water-oil emulsion would contain both the genotype 
and the phenotype. (Figure 1.5) 
Since enzymes and affinity reagents exit in nature are mostly proteins or peptides, 
directed evolution can be employed to improve the properties of these polypeptide 
molecules according to the demand of researcher 
[68]
. Early polypeptide selections focus 
on evolution of antibodies from random library or optimization of antibodies that 
previously existed 
[60]
. They have also been applied for the discovery and delivery of 
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drugs 
[67]
. Selecting functional molecules from random library can also help us explore 
the frequency of functional molecules in a pool and thus leads to further understanding 
the evolution of functional proteins in nature 
[69]
.  
 
1.4.1 In vivo display of polypeptides. In vivo selection strategies include phage 
display 
[17]
, bacterial display 
[41]
 and yeast display 
[42]
. Both phage display and bacterial 
display are first reported in 1980s 
[43] [44] [45]
, while yeast display, which involves 
eukaryotic cells, is first reported in 1997 
[46]
. Phage display was initially designed to use 
phage as an expression vector, but gradually these methods developed into in vivo 
selection strategies.  
 
The principles for in vivo display strategies are quite similar 
[47]
. A random DNA 
library, which represents the genotype, is transformed in to certain type of cells, such as 
E.coli or yeast. For bacteria display and yeast display, the expressed protein, which is the 
phenotype, is displayed as fusion of a membrane or coat protein on the surface of the cell. 
For phage display, a helper phage, which enables packaging of the phage DNA and the 
assembling of mature viruses with expressed protein as part of the outer coat on the coat 
protein. The cells containing expressed protein that binds with target are either eluted 
(phage) or screened through fluorescent-activated cell sorting (FACS) for the next round 
of screen (Figure 1.6) 
[49]
. 
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Figure 1.5 Key features of different selection strategies for peptide/protein evolution. For 
phage display, the phenotype is displayed on the coat protein while the genotype is 
packed inside the phage. For yeast or bacterial display, the phenotype is linked with 
membrane or surface protein while genotype is inside the cell. For ribosome display, 
genotype (mRNA) and phenotype are non-covalently linked by the ribosome. For mRNA 
display, genotype (mRNA-cDNA) and phenotype are covalently ligated by puromycin. 
For in vitro compartmentalization, genotype exists with the phenotype inside the water-
oil emulsion. 
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Figure 1.6 Principle of phage display selection 
[62]
. Peptides and proteins displayed by 
phages are mixed with the target, which is attached to magnetic beads or other staionaery 
 20 
support. After a certain amount of incubation time, the unbound phages are washed while 
the bound phages are eluted and recovered, generally through brief exposure to extremes 
of pH values. At this point, the phages can either grow for the next round of selection or 
be sequenced for future analysis. Reprinted with permission from Kehoe, J.W.; Kay, B.K. 
Chem. Rev. 2005, 105, 4056-4072. Copyright 2005 American Chemical Society.  
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The main advantage of in vivo displays is that it provides a cellular environment 
to study any proteins that involved in process in living organisms, such as proteins 
participating in cell signaling pathways or proteins interact with cell-membrane proteins 
[51][52]
. The affinity reagents can be selected with in vivo targeting against molecules that 
presents at their original locations and conformations 
[57]
. In yeast display, the eukaryotic 
nature of yeast made it possible to study complex proteins and its eukaryotic properties 
benefits targets that are expressed by mammalian cells 
[42]
. These methods are also well 
established and have been applied for many purposes, such as creating affinity reagent for 
different purpose, engineering of antibodies and directed evolution of enzymes 
[53]
.  
However, there are several other disadvantages of in vivo evolution. The 
efficiency of transformation limits the diversity of the random library significantly. 
Normal library size of phage display is only 10
7
 to 10
8
. If a scheme calls for more 
diversity after each round, more cells need to be transformed and the amount labor 
increases enormously, which prevents the evolution through many generations 
[14] [54]
. 
When the library is too long, it would be almost impossible to transform the library into 
cells, thus limits the size of protein evolved. Also, the targets are limited due to the cells 
involved, i.e. any target that would kill or lysate the cells or stop the cells from 
reproducing would not be suitable for the selection. 
The cell environment could potentially be a disadvantage too, as the packaging 
process of proteins can serve as an unwanted evolution pressure for those proteins that do 
not express of fold well in vivo 
[14]
. During the process of selection, the enormous size 
and surface of phage, bacteria or yeast cells might complicate the selection process and 
cause undesirable interactions 
[55]
. 
 22 
1.4.2 In vitro evolution of polypeptides. In vitro evolution of polypeptides 
includes ribosome display and mRNA display. It normally starts with a random DNA 
library, which would be transcripted into message RNA (mRNA) and translated into 
peptide or protein. The prerequisite step of selection is that translation product would be 
coupled with the mRNA, which carries the genetic information of sequence. The 
translated polypeptides that bind the target would be recovered and amplified through its 
genotype with PCR 
[15] [16]
 (Figure 1.7). 
In comparison with in vivo evolution, in vitro selection manages to overcome 
most of the disadvantages mentioned above. The whole process is selection instead of 
screening and the diversity of library is now limited by the number of mRNA or ribosome 
that existed in a tube, which is typically 10
12
 to 10
13
 diversity, and mutations are easily 
introduced through error prone PCR if necessary 
[54]
. There are much fewer limitations to 
the size of desired protein reagent or the types of target. The unwanted selection pressure, 
which would be created by the whole process of folding, transporting, membrane 
insertion and complexation can be avoided with cell-free in vitro selection 
[14]
. But both 
methods still have their own advantages and disadvantages comparing with each other, 
which would be discussed in the following sections. 
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Figure 1.7 Selection scheme for ribosome display and mRNA display. a) In ribosome 
display, double stranded DNA was transcribed and translated in vitro, the translated 
polypeptide is ligated with mRNA by ribosome. After selection, the recovered bound 
molecules are reverse transcribed and amplified by PCR. b) In mRNA display, after 
transcription, a psoralen-DNA-puromycin linker is crosslinked with mRNA. The mRNA-
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polypeptide fusion is reverse transcribed and bound with target. The bound molecules are 
recovered and PCR amplified. 
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1.4.2.1 Ribosome display. In ribosome display, the starting DNA sequence 
contains coding for the library and a spacer sequence which lacks a stop codon. When the 
transcribed mRNA is translated, the spacer sequence, which would be attached to the 
peptidyl tRNA, occupies the ribosomal tunnel and provides extra flexibility which allows 
the protein to fold into certain structure. The genotype (mRNA) and phenotype 
(polypeptide) are linked together through the non-covalent bond with ribosome. The 
bound can be further stabilized by high concentration of magnesium ions and lower 
temperature, but the stability would be sufficient for most selections. The fusion the binds 
with the target, and the bound fusions would be eluted, reverse transcribed and amplified 
with PCR 
[56]
. 
 
For ribosome display, it has all the advantages for in vitro selection, such as the 
diversity in the library and freedom in choosing target. As an in vitro process, it allows 
the user to take full control of the selection process, such as where the mutations should 
occur in the sequence or which residue types should be introduces 
[58]
. Compared with 
mRNA display, it is more widely used and studied, with more examples for comparison. 
The whole process has fewer steps and is easier to manipulate in terms of labors. 
 
However, there are several disadvantages with ribosome display. Much like phage 
display, ribosome display has a large “display object”-ribosome, with molecular weight 
of more than 2000kDa while most polypeptides being selected as ligand are smaller than 
10kDa. The size and surface of large display object would complicate of polypeptide 
conditions, as the unpredictable interaction between ribosome complex and translated 
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polypeptide leads to loss of potential binders while the undesired interaction between 
ribosome and target protein leads to amplification of non-binders 
[55]
.  
 
During the ribosome display, because of the existence of ribosome, the mRNA 
can only be reverse transcribed after the selection to maintain its structure. Thus the 
single stranded mRNA has the potential to fold into secondary structure and RNA 
aptamers might be enriched unwontedly through the selection process. Also, to keep the 
non-covalent bond in the fusion, stringency of selection is limited and it would be 
challenging to reduce background binding in the process of selection.  
 
1.4.2.2 Messenger RNA display. The mRNA display was first applied in 1997 by 
Szostak group 
[16]. The key element in mRNA display is the puromycin linker at the 3’ 
end of mRNA. Puromycin is an analogue of 3’end of a tyrosyl-tRNA. After the whole 
coding region is translated, the fused puromycin enters the A site of ribosome when the 
ribosome proceeds to form a peptide bond between puromycin and the C-terminal amino 
acid residue of the polypeptide chain. The genotype, mRNA, is thus covalently ligated 
with the phenotype, polypeptide. 
 
A light-induced psoralen crosslinking reaction was employed to attach the 
puromycin linker to the 3’ end of mRNA [59]. To provide enough flexibility and proper 
length for the puromycin to enter ribosome, a linker with 25 deoxyadenosine and 2 
Spacer 9 is fused with mRNA after transcription together with puromycin 
[58]
. The dA 
sequence would also provide a way to purify in vitro translation product using oligo dT 
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cellulose column after translation step. After purification and reverse transcription, the 
genotype-phenotype fusion is incubated with the target and the binders would be 
recovered by elution and PCR amplified. 
 
Aside from the advantages shared by in vitro selections, mRNA display has 
several advantages over ribosome display. The reverse transcription step before selection 
eliminates the possibility of selecting RNA aptamers. As the mRNA/cDNA and 
poplypeptides are covalently linked with each other, the only thing that limits the 
selection condition, such as buffer and temperature, is the stability of target protein. 
Stringency of selection can be increased each round by increasing denaturing condition 
such as guanidine hydrochloride without worrying about breaking the bond in fusion 
library 
[60]
.  
 
Also, the puromycin linker is very small comparing (about 500Da) with ribosome 
or phage, which overcomes the issue of “large display object” and the chance of causing 
undesirable binding is much smaller. In general, mRNA display not only possesses the 
advantages of in vitro selection, but also overcomes most of the “background issue” 
compared with ribosome display 
[55]
. 
 
However, it remains unclear that how the mRNA-puromycin-polypeptide fusion 
leaves ribosome after in vitro translation step. The ribosome could unfold to open the 
exiting tunnel to let the fusion slide sideways, or the fusion could thread through the 
tunnel, but there is still possibility that ribosome might not be fully removed after 
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translation, thus might rise potential issue for the selection 
[61]
. Another problem with 
mRNA display is probably that the labor work for mRNA display is demanding and 
tedious. A typical mRNA display selection takes about a week per round, and the rather 
daunting experimental protocol makes it hard for every lab to use 
[55]
. 
 
1.4.3 Other polypeptide selection strategies. Some of the other selection 
schemes include In vitro compartmentalization (IVC) and CIS display. IVC mimics the 
cellular compartmentalization by packing genotype (DNA) and in vitro transcription 
translation element within the cell-sized aqueous droplets in the water-oil emulsion 
[48]
. It 
has special advantages in evolving multiple turnover enzymes, since it would be very 
hard to link the enzyme with its reaction product, especially in a multiple turnover 
reaction 
[63]
. The conditions of selection can be monitored by changing the chemical 
environment in different droplets 
[64]
. CIS display employed a DNA replication initiator 
protein (Rep A) to bind exclusively with the genotype (template DNA) to phenotype (the 
polypeptide expressed) 
[65]
. Its advantage lies in the stability and speed by using a DNA 
template instead of RNA template. This technique has been applied commercially for 
peptide and protein selection 
[66]
.  
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2.1 Contributions 
The following chapter describes a collaborative research project to develop a 
DNA aptamer with high specificity and affinity against alkaline proteins. Hanyang Yu 
conducted the initial de novo evolution starting from a naïve DNA library using capillary 
electrophoresis as the partitioning technique to enrich aptamers that bound H4 aptamer, 
cloned and sequenced 23 clones after 4 rounds of selection. Hanyang Yu predicted the 
secondary structure and free energy values of these clones with mFold. Hanyang Yu and 
Ms. Jiang measured the binding affinity of these 23 clones with dot blot. Ms. Jiang made 
a doped library with 15% doping rate from the best clone and conducted the directed 
evolution using both capillary electrophoresis and magnetic beads. Ms. Jiang cloned and 
sequenced 8 clones from capillary electrophoresis employed selection and 8 clones from 
magnetic beads employed selection after 3 rounds of selection. Ms. Jiang predicted the 
secondary structure and free energy values of these clones with mFold and measured the 
binding affinity with dot blot under low salt conditions. Hanyang Yu measured the 
binding affinity with dot blot under high salt conditions and conducted the site-directed 
mutations and foot-printing of the best clone to study its binding motif. Hanyang Yu, Dr. 
Chaput and Ms. Jiang wrote the manuscript. The result of this work was published on 
ChemBioChem. 
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2.2 Abstract 
Aptamers are single-stranded nucleic acids that fold into stable three-dimensional 
structures with ligand binding sites that are complementary in shape and charge to a 
desired target. Aptamers are generated by an iterative process known as in vitro selection, 
which permits their isolation from pools of random sequences. While aptamers have been 
selected to bind a wide range of targets, it is generally thought that these molecules are 
incapable of discriminating strongly alkaline proteins due to the attractive forces that 
govern oppositely charged polymers (e.g., polyelectrolyte effect). Histones, eukaryotic 
proteins that make up the core structure of nucleosomes are attractive targets for 
exploring the binding properties of aptamers because these proteins have positively 
charged surfaces that bind DNA through noncovalent sequence-independent interactions. 
Previous selections by our lab and others have yielded DNA aptamers with high affinity 
but low specificity to individual histone proteins. Whether this is a general limitation of 
aptamers is an interesting question with important practical implications in the future 
development of protein affinity reagents. Here we report the in vitro selection of a DNA 
aptamer that binds to histone H4 with a Kd of 13 nM and distinguishes other core histone 
proteins with 100 to 480-fold selectivity, which corresponds to a ΔΔG of up to 3.4 
kca/lmol. This result extends our fundamental understanding of aptamers and their ability 
to fold into shapes that selectively bind alkaline proteins. 
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2.3 Introduction 
Aptamers are short nucleic acid polymers (DNA or RNA) that fold into well-
defined three-dimensional structures whose surfaces include binding sites that are 
complementary in shape and charge to a desired target. Aptamers were first discovered in 
1990 when two labs independently reported the generation of RNA molecules with 
specific ligand binding properties from pools of random sequences.
[1] 
In the original 
papers, Ellington and Szostak called these RNA molecules “aptamers” from the Latin 
aptus, to fit, while Tuerk and Gold labeled this process “systematic evolution of ligands 
by exponential enrichment” (SELEX). SELEX is sometimes referred to as in vitro 
selection or test tube evolution since this laboratory procedure mimics the natural process 
of Darwinian evolution. 
[2]
 In these experiments researchers create a survival-of-the-fittest 
environment in which individual molecules compete against one another to overcome a 
selective pressure that is predefined, but often requires binding to a desired target. The 
small fraction of molecules that meet this requirement are collected and amplified to 
restore the population to its original size and create progeny molecules that can be further 
challenged in subsequent rounds of in vitro selection and amplification. Progeny 
molecules have the ability to inherit genetic mutations, either by intentional mutagenesis 
or through random mistakes made by a polymerase that can improve the fitness of the 
molecule for its intended function or lead to deleterious effects that cause the sequence to 
be removed from the pool. 
The ability to harness the power of evolution at the molecular level has led to the 
development of straightforward procedures for creating tailor-made affinity reagents in 
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the laboratory.3 Since those initial experiments aptamers have been shown to display a 
wide range of structural plasticity, and it is now clear that aptamers can be selected to 
bind almost any kind of molecular target from small molecules to whole cells.
[2a-e] [4]
 One 
major hallmark of aptamers is their ability to bind discrete targets with high specificity. 
An aptamer generated to bind theophylline, for example, recognizes its cognate ligand 
10 000 times better than it recognizes caffeine, which differs from theophylline by only 
one methyl group. 
[5]
 More recently, our lab developed an aptamer that recognizes an 
acetyllysine posttranslational modification in a polypeptide sequence with 2400-fold 
specificity. 
[6]
 
The strong recognition properties of aptamers combined with the ease by which 
they can be produced has fueled strong interest in the use of aptamers as affinity reagents 
in many areas of biotechnology and molecular medicine. 
[7] 
Aptamers function efficiently 
in standard protein-binding assays, including ELISA, 
[8]
 Western blot analyses, 
[9]
 
microarrays, 
[10] 
and affinity chromatography. 
[11]
 In one example, an L-selectin aptamer 
was used to purify the human L-selectin receptor from Chinese hamster ovary cells.11 In 
this case, pure protein was obtained in a single step with 15000-fold enrichment and 83 % 
recovery. Aptamers have also been used as recognition elements in a variety of 
biosensors and analytical devices.
 [12]
 For example, an aptamer-based dipstick assay was 
developed to detect cocaine, 
[13]
 and a colorimetric assay now exists to monitor the levels 
of lead in the environment.14 Aptamers are also gaining attention as therapeutic agents. 
[15]
 The aptamer Macugen is now approved by the FDA for the treatment of patients 
affected by neovascular age-related macular degeneration.16 This VEGF aptamer 
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functions as a drug by inhibiting the binding of VEGF-165 to its receptor. In clinical 
trials, 80 % of the patients treated with this aptamer showed stable or improved vision 
three months after treatment. 
[16]
 
Despite the success that aptamers have achieved in recent years, many basic 
questions remain about how these molecules fold into shapes with discrete ligand-binding 
functions. 
[33] [34] [35] 
The ability for aptamers to target alkaline proteins constitutes an 
important aspect of this general problem as many proteins have highly basic surfaces. 
Clearly a greater understanding of the binding properties of aptamers is needed if these 
molecules are to be used as affinity reagents on a scale as large as the human proteome. 
[17]
 Conventional wisdom suggests that aptamers should be incapable of folding into 
structures that selectively recognize positively charged proteins due to the attractive 
forces that govern polymers of opposite charge. This problem, commonly referred to as 
the polyelectrolyte effect, occurs when negatively charged polymers like DNA interact 
with positively charged polymers like protein to create a ligand binding interaction that 
releases water molecules and counter ions that previously solvated overlapping regions of 
both polymers. 
[18]
 The magnitude of the polyelectrolyte effect is an important constraint 
on the ability of aptamers to target alkaline proteins, as aptamers would need to first 
overcome the barrier that defines the complementary attraction of oppositely charged 
polymers in order to bind a basic protein with high specificity. While the polyelectrolyte 
effect has been the subject of previous computational studies, 
[19]
 very little experimental 
consideration has been given to the thermodynamic properties of aptamers and their 
ability to bind alkaline proteins. 
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We chose to explore this problem by attempting to evolve DNA aptamers with 
high specificity to histone H4. Histones are eukaryotic proteins that package DNA into 
nucleosomes. The core proteins that make up the nucleosome are histones H2 A, H2 B, 
H3, and H4. 
[20]
 Each of the core histone proteins has a globular domain that interacts 
with other histones to form the histone octamer and an amino-terminal tail peptide which 
contains 20-35 residues and extends from the surface of the nucleosome 
[36]
. These 
peptides are rich in basic amino acids and have become targets for many post 
translational modifications. The main types of modifications are acetylation, methylation, 
ubiquitination and phosphorylation. Notably, some, although very few of these 
modifications locate on the C-terminus or core region of the protein. Since these tail 
peptides can be modified at several different amino acid positions with several different 
types of modifications, and each site can be modified or unmodified, the combinations of 
different types of post translational modifications are enormous.  
These modifications play important roles not only in regulation of gene 
expression as well as DNA damage repair and DNA replication and recombination, but 
also in epigenetic regulation 
[37]
. It is commonly believed that like genetic code, these 
post-translational modifications can be read by different machineries in cell as “the 
histone code” [38]. Similar as genetic code, for example, if the ribosome reads ‘TAG’, it 
can be translated into ‘stop the translation’, the histone code can also be translated into 
different functions. For example, acetylation is related with activation of transcription and 
deconsenation of chromatin 
[40]
 while methylation is associated with repression of 
transcription and condensation of chromatin 
[41]
. Methylation also assists the packing of 
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inactive X chromosome in female organisms into a tight form of chromatin called 
heterochromatin 
[42]
.  
Post translational modifications also have a ‘crosstalk’ pattern where one 
modification can trigger or suppress a different modification on a different site and form 
a code to determine the transcriptional outcome 
[46]
. The first crosstalk pattern discovered 
is the phosphorylation of serine 10 on H3, which can stimulate the ability of Gcn5 to 
acetylated lysine 14 on H3 
[47]
. The combinations of these modifications can also regulate 
gene transpiration. A more complex model happens between H3S10P and H4K16Ac 
[48]
, 
as kinase PIM1 bind to the FOSL1 enhancer, it phosphorylated serine 10 on H3 tail 
peptide, which creates a binding site for phosphorserine binding protein 14-3-3, and the 
interaction between 14-3-3- and histone acetyltransferase MOF triggers the acetylation of 
lysine 16 on H4. The H4K16Ac can form a binding site for Brd4, which is a component 
of a kinase P-TEFb, which phosphorylates the C-terminal domain of RNA polymerase II 
to facilitate the transcription elongation. These studies can help us understand more about 
the biological process that associate with DNA in eukaryotic cells.  
Post translational modifications are also often related with diseases. For example, 
comparing with normal cells, cancer cells exhibit decreased monoacetylated and 
trimethylated form of H3 and H4 
[43]
. The reduction of H4K16Ac, which is a marker of 
aging at the telomeres 
[44]
, and H4K20Me3, which impairs DNA damage control, is 
observed as an early event throughout the tumor development. So detection of these post 
translation modifications can serve as a way to diagnose early stage or potential cancer 
that occurs in human. However, despite their significances, antibodies that can recognize 
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these post translational modifications with high affinity and specificity are rare 
[45]
. Since 
we managed to evolve an DNA aptamer that recognize the important H4K16Ac 
modification with more than 2400 fold specificity, aptamers might serve as a useful 
alternate in the recognition of histones and their modifications 
[6]
.  
We hypothesized that histone H4 represented an ideal target for this investigation 
as a previous study by our lab produced a histone-binding aptamer with high affinity but 
low specificity. 
[21]
 Similar results were also achieved by Gonzalez and co-workers in 
their generation of DNA aptamers to Leishmania infantum histone proteins H2 A and 
H3.22 Collectively, these examples led us to wonder whether this was a general problem 
of aptamer binding or a specific problem related to the previous selection strategies. To 
explore this question in greater detail, we carried out an in vitro selection using counter 
selection steps to determine whether aptamers could be generated that distinguished 
histone H4 from the three other core histone proteins. The best aptamer identified in this 
selection binds to histone H4 with low nanomolar affinity and discriminates against 
histone proteins H2 A, H2 B, and H3 by ~100-500-fold. By comparison, all previous 
selections yielded aptamers with only two to five fold specificity. This result 
demonstrates that aptamers have the ability to fold into structures that distinguish highly 
basic proteins of similar structure and function; however, these sequences are sufficiently 
rare that they require strong counter selection conditions to isolate 
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2.4 Result 
2.4.1 Selection for single-stranded DNAs that bind to histone H4. DNA 
sequences that bind to histone H4 were isolated by iterative rounds of in vitro selection 
and amplification. The initial pool contained 10
12
 unique single-stranded DNA molecules 
with a central random region of 50 unbiased nucleotide positions flanked on both sides 
with distinct primer-binding sites. To isolate molecules with affinity to the N-terminal 
region of histone H4, peptides reflecting the N-terminal tail of histone proteins H2 A, 
H2 B, H3, and H4 were used in place of the whole proteins. This substitution was feasible 
because this region of the protein remains natively unstructured when DNA threads itself 
around the histone octamer to form the nucleosome core. 
[20]
 The selection strategy 
(Figure 2.1) included a negative selection step to remove molecules that bound the off-
target histone sequences of H2 A, H2 B, and H3, followed by a positive selection step to 
isolate molecules with affinity to the desired histone H4 target sequence. For each round 
of selection, the pool was incubated with the off-target peptides H2 A, H2 B, and H3, 
which were modified with a C-terminal biotin residue to enable their capture on a 
streptavidin-affinity matrix. Molecules that remained in the pool were incubated with the 
desired H4 peptide, and functional aptamers were separated from the unbound pool by 
injecting the mixture onto a neutral coated capillary. Five injections were made for each 
round of selection and 10
11
 molecules were sampled in the first round of the selection. 
Capillary electrophoresis (CE) was chosen for the positive selection step because 
this technique leads to a higher partitioning efficiency than is commonly observed for 
traditional gravity filtration. 
[25]
 This in turn reduces the number of selection cycles 
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required to generate high quality aptamers from ≥10 to just three or four rounds of 
selection and amplification. In the case of IgE, for example, an aptamer was generated 
after four rounds of CE-based selection that exhibited similar binding properties to an 
aptamer produced after 15 rounds of traditional selection. 
[26] 
A second major advantage 
of CE is that aptamer binding occurs free in solution, which obviates the need for 
complicated conjugation chemistry that can occlude surface binding sites or alter the 
native protein structure. Collectively, these advantages make CE an increasingly popular 
separation technique for the in vitro selection of aptamers that bind peptides and proteins. 
[27]
 We have previously used this method to generate a DNA aptamer with >2000-fold 
specificity to an acetylated lysine residue in a short polypeptide sequence. 
[6]
 
To favor the selection of aptamers with high specificity to histone H4, the ratio of 
the DNA pool to the different histone tails was adjusted in the negative and positive 
selection steps to maintain high selective pressure on the pool of evolving molecules. In 
rounds one and two, the ratio of the DNA pool to the off-target histones was 100:1, which 
was stringent enough to remove DNA sequences that bound the off-target peptides, but 
permissive enough to allow desirable molecules to remain in the pool. The stringency 
was then increased in rounds three and four by reducing the ratio to 1:1, which favored 
the removal of molecules with weaker affinity to the H2 A, H2 B, and H3 peptide 
sequences. For each round of positive selection, the ratio was reversed such that the H4 
peptide was present at limiting amounts relative to the DNA pool (1:1000). By limiting 
the target peptide, we aimed to increase competition between the pool and desired histone 
tail. After four rounds of selection, the DNA pool was cloned and sequenced. We 
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obtained 23 clones and analyzed their sequences by calculating their predicted secondary 
structures using the computer program mFold (Figure S2.1). Five of the clones are 
predicted to fold into structures that are dominated by a simple stem-loop or internal 
bulge motif. The remaining clones adopt more complicated structures that contain tandem 
stem-loop motifs. The presence of many highly structured sequences suggests that 
sophisticated functions, such as the ability to discriminate subtle differences between 
peptides of similar sequence and composition, require molecules with significant 
structural complexity. 
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Figure 2.1. In vitro selection strategy used to generate DNA aptamers with high affinity 
and specificity to histone H4 protein. For each round of selection and amplification, the 
pool of DNA was pre-cleared by removing DNA sequences with affinity to the N-
terminal tails of histone proteins H2A, H2B and H3. Molecules collected in the flow-
through were incubated with the N-terminal tail of histone H4 and the bound fraction was 
separated from the unbound pool by capillary electrophoresis. The set of bound 
molecules was recovered, amplified and used to generate a new pool of sequences for 
input into the next round of selection. Experiment done by Hanyang Yu 
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2.4.2 Affinity and specificity of the DNA aptamers. Of the 23 sequences, eight 
representative clones with different secondary structures were chosen for further analysis. 
The eight sequences were constructed by solid-phase DNA synthesis, purified by gel 
electrophoresis, and assayed for affinity to histone H4 whole protein by dot blot analysis. 
[24]
 Close inspection of the dissociation constants (Kd values) reveal that all eight clones 
bind to histone H4 with Kd values of 1 to 10 nM, indicating these sequences are all 
capable of high affinity binding (Table 2.1). To examine the specificity of the selected 
aptamers, dissociation constants were measured for the four strongest binders to the off-
target whole proteins H2 A, H2 B, and H3. In keeping with the literature, [28] this study 
defined specificity as the ratio of the off-target Kd to the on-target Kd, and aimed to 
produce aptamers with at least 100-fold specificity to each of the off-target proteins. 
Results from our initial specificity study demonstrate that the selected clones are 
relatively specific against histone proteins H2 A and H2 B (50- to 150-fold), but fail to 
discriminate histone H3 by more than tenfold (Table 2.2). Creating aptamers that 
distinguish the N-terminal tail of histone H4 from the N-terminal tail of histone H3 is a 
challenging problem as previous selections performed in the absence of counter selection 
methods yielded aptamers with only two- to fivefold selectivity. 
[21] [22] 
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2.4.3 Salt effects. Because electrostatic attraction between the negatively charged 
DNA backbone and positively charged histone protein might account for the low 
selectivity observed for the selected aptamers, we decided to examine the role of metal 
ions on ligand binding affinity. By increasing the concentrations of monovalent and 
divalent metal ions in the binding buffer, we aimed to stabilize the tertiary structure of the 
aptamer fold and simultaneously satisfy competing charges on the protein surface. To test 
this possibility, we chose clone 4.33 for further analysis as this sequence showed the 
highest degree of specificity to histone H3. Raising the salt concentration from 100 mM 
NaCl and 5 mM MgCl2 to 500 mM NaCl and 10 mM MgCl2 increased the binding 
specificity of clone 4.33 for histone H4 versus histone H3 from tenfold to nearly 30-fold 
(Table 2.3). A similar increase in specificity was observed against histones H2 A and 
H2 B (up to 422- and 86-fold, respectively). We noticed that increasing the salt 
concentration beyond this level did not translate into further increases in specificity, 
indicating that all of the metal binding sites on the aptamer and protein were saturated 
under the higher salt conditions (data not shown). We speculate that the change in 
specificity is due to the formation of new intramolecular contacts within the aptamer 
structure. This hypothesis is consistent with the observation that clone 4.33 adopts a third 
stem-loop motif when its predicted secondary structure is calculated under conditions that 
simulate the higher salt concentration (Figure S2.2). 
 
 
 51 
 
 52 
2.4.4 Directed evolution. In an effort to isolate aptamers with greater specificity 
for histone H4, we used directed evolution to optimize clone 4.33 for improved ligand 
binding affinity and specificity. We created a second-generation library based on the 
parent sequence of clone 4.33 in which each nucleotide position in the aptamer sequence 
was doped with a 15 % mixture of the other three nucleotides. This level of mutagenesis 
was intended to optimize contacts within the aptamer structure and produce mutations 
that would lead to greater discrimination between histone H4 and the other three histone 
proteins. As a precaution new primer binding sites were added to the flanking regions to 
avoid the unwanted enrichment of aptamers from the original library. The doped library 
was subjected to three iterative rounds of directed evolution using two different selection 
strategies. The first strategy was performed in a manner identical to the original in vitro 
selection with a negative selection step performed on streptavidin-coated beads to remove 
molecules with affinity to the off-target sequence followed by a CE-based positive 
selection step to recover molecules that bound the N-terminal tail of histone H4. For each 
selection round, the ratio of the off-target to pool and on-target to pool was maintained at 
1:1 and 1:1000, respectively. In the second selection strategy, both the negative and 
positive selection steps were performed using traditional affinity chromatography 
methods to separate the bound molecules from the unbound pool. After three rounds of 
directed evolution, both libraries were cloned and sequenced to examine the diversity of 
molecules that remained in each pool. 
Eight clones from the CE-based selection and nine clones from bead-based 
selection were aligned with clone 4.33 (Figure S2.2). The average number of mutations 
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per sequence was 7.6, which closely approximates the number of mutations expected for 
a library of 50 nucleotides that was doped at a level of 15 % per nucleotide position. 
Close inspection of the aligned sequences reveals several small patches of conserved 
nucleotides that are distributed among numerous single-point mutations. To examine the 
extent to which any of the selected sequences showed higher selectivity for histone H4, 
we randomly chose three sequences from the output of each selection and measured their 
affinity and specificity for histone H4. Each sequence was synthesized by solid-phase 
DNA synthesis, purified by gel electrophoresis, and assayed for affinity to histone 
proteins H2 A, H2 B, H3, and H4. Surprisingly, only clone 3.13 isolated from the CE-
based selection showed high selectivity to histone H4 (Table 2.4). The remaining clones 
were unable to distinguish histone H4 from histone H3 by more than ~20-fold, which is 
less than the parent sequence (clone 4.33). Aptamer CE-3.13, however, binds histone H4 
with a Kd of 13 nM and discriminates against histone proteins H2 A, H2 B, and H3 by 
477-, 165-, and 100-fold, respectively (Figure 2.2). This result emphasizes the challenge 
of isolating aptamers with reasonable selectivity to highly basic proteins, but provides 
evidence that such sequences are not so rare that they cannot be discovered by in vitro 
selection. 
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Figure 2.2. Solution binding affinity and specificity of aptamer CE-3.13. Equilibrium 
binding affinity was measured by dot blot analysis for histone proteins H4 (●), H3 (■), 
H2 B (◆) and H2 A (▲). Experiment done by Hanyang Yu 
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2.4.5 Studies of site-directed mutations. To examine the genetic changes that 
led to improved specificity, we compared the predicted secondary structure for the parent 
sequence to the evolutionary optimized variant. This analysis demonstrates that four of 
the eight single-point mutations occur in regions of the sequence that define the predicted 
secondary structure (Figure 2.3A). We therefore reverted each of the four point mutations 
individually back to their original nucleotide, and measured the solution binding affinity 
for histone proteins H3 and H4. While the four revertant clones recognized histone H4 
with Kd values that are within twofold of aptamer CE-3.13, none of the sequences was 
able to distinguish histone H3 by more than 20-fold (Figure 2.3B). This loss in selectivity 
suggests that each of the four point mutations play an important role in the folding and 
recognition properties of aptamer CE-3.13. 
To further explore the evolved mutations, we generated variants that contained 
compensatory mutations in stem-loop regions of the predicted secondary structure. Two 
clones were constructed that restore Watson–Crick base pairs to the C23G and G41A 
revertants by changing the G:G and C:A mismatches to C:G and T:A base pairs, 
respectively. These engineered clones bind histone H4 with Kd values equivalent to the 
evolutionary optimized aptamer, but again fail to restore selectivity to the aptamer 
sequence (Figure 3B). This result demonstrates that the selected mutations, G23C and 
A41G, which form G:C and C:G base pairs in aptamer CE-3.13, impart additional 
functionality beyond simply maintaining a contiguous helix in the stem-loop region of the 
secondary structure. One possibility is that these mutations form new contacts within the 
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architecture of the aptamer that rigidify its structure and limit the amount of flexibility in 
and around the ligand-binding pocket. 
To gain a better understanding of how the structure of aptamer CE-3.13 
contributes to its recognition of the N-terminal tail of histone H4, we performed a 
hydroxyl radical footprinting analysis in the absence and presence of histone proteins 
H2 A, H2 B, H3, and H4. Consistent with the high specificity of aptamer CE-3.13 for 
histone protein H4, protection of the DNA backbone occurred to a greater extent for 
histone H4 than for any of the other three histone proteins (Figure S2.4). Careful analysis 
of the resulting gel indicates that histone proteins H2 A, H2 B, and H3 protect residues 
34–38 of the aptamer. This relatively small region is likely due to weak electrostatic 
interactions between the DNA backbone and the three histone proteins. However, the 
case is quite different for histone H4, which protects a much larger region of the aptamer 
from hydroxyl cleavage. Here a clear footprint is observed for residues 31–45, which 
constitute a strong binding interface with histone H4. Combining this information with 
the predicted secondary structure suggests that the second stem-loop motif forms a 
binding pocket that is complementary in shape and charge to the N-terminal tail of 
histone H4. Indeed, three of the four genetic mutations observed in aptamer CE-3.13 
occur in this region of the oligonucleotide, which implies that each of these mutations 
play an important role in the binding of histone H4. The fourth mutation, which occurs in 
the first stem-loop motif could help with aptamer stability by improving the packing 
interactions between the two stem-loop motifs. This result is consistent with the 
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interpretation that the four selected mutations increase protein binding specificity by 
rigidifying the aptamer structure. 
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Figure 2.3. Aptamer binding motif and analysis. A) Sequence alignment of aptamers 4.33 
and CE-3.13 showing the eight genetic mutations that gave rise to an evolutionary 
optimized variant with high specificity to histone H4. B) The predicted secondary 
structures of aptamers 4.33 and CE-3.13 are shown with the mutated positions 
highlighted in red and green, respectively. Binding affinity and specificity (parentheses) 
of each reversion and compensatory mutation is shown next to the structure of aptamer 
CE-3.13. Experiment done by Hanyang Yu 
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2.4.6 Implications of aptamer selection. We have applied the strategy of in vitro 
selection and directed evolution to isolate a single-stranded DNA molecule with high 
affinity and specificity to histone H4. When we began this study it was not obvious a 
priori that a random pool of DNA sequences would contain a nucleic acid molecule that 
folded itself into a shape that recognized an alkaline protein with high affinity and 
specificity. A previous study by our lab that aimed to produce a set of DNA aptamers to 
histone H4 yielded a number of high affinity sequences (Kd ~5-10 nM); however, the 
best sequence could only discriminate histone H3 by a factor of five. 
[21] 
Similar results 
were obtained by Ramos and co-workers on histone proteins H2 A and H3, which 
produced aptamers with only two- to threefold specificity.22 Whether this was a general 
problem of aptamers (that is, the potential inability of negatively charged polymers to 
fold into shapes that recognize positively charged polymers with high selectivity) or 
simply a limitation of the previous selection strategy was unclear. We therefore designed 
a new selection strategy that included the use of stringent counter selection steps between 
iterative rounds of selection and amplification, since this approach has been widely used 
to generate aptamers with specific ligand binding properties. 
[5] [6] [29]
 The goal of this 
selection was to remove DNA molecules from the pool that exhibited high affinity to the 
off-target histone proteins H2A, H2 B, and H3. In doing so, we aimed to address the 
broader question of whether aptamers could be used to bind alkaline proteins with high 
specificity. 
Comparison of the binding properties of the aptamers isolated by directed 
evolution (Table 2.4) reveals a striking difference in the tolerance of each molecule for 
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the off-target histone proteins. For example, aptamer CE-3.13, which was isolated using 
the capillary electrophoresis method, is significantly more fit in terms of its ability to bind 
histone H4 than all of the other DNA aptamers. This aptamer binds to histone H4 with a 
solution binding affinity of 13 nM and distinguishes the three remaining core histone 
proteins by a factor of 100- to 477-fold, which corresponds to a binding energy of up to 
3.4 kcal mol−1. In contrast, the less fit aptamers also bind to histone H4 with low 
nanomolar affinity, and are able to distinguish histone proteins H2 A and H2 B with high 
specificity (≥100-fold), but struggle with their ability to discriminate histone proteins H4 
and H3. This problem was observed in our previous selection and likely stems from the 
fact that both proteins have similar sequence composition in their N-terminal tails, which 
was the protein region targeted in both selections. While it is exciting to wonder whether 
the isolation of aptamer CE-3.13 was due to the high partitioning efficiency of the 
capillary electrophoresis-based separation, many additional aptamers will need to be 
tested before this question can be answered. 
One interesting observation to come from the aggregate set of binding data is that 
aptamers with high affinity are not automatically more specific for their target ligands. 
Although it has long been assumed that the easiest way to improve aptamer specificity is 
to increase its shape and charge complementary for a given target, 
[30]
 a recent study by 
Szostak and co-workers suggests that specificity is a physical property that emerges when 
biopolymers adopt folded structures that are reinforced with additional intramolecular 
contacts. 
[31]
 This revised aptamer binding theory takes into account the free energy term 
provided by intramolecular contacts that contribute to the overall stability of the tertiary 
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structure. According to this model, it is expected that as an aptamer evolves from an 
initial simple motif to a more complex tertiary structure it will acquire additional 
structural elements that allow it to form a more rigid ligand-binding pocket that is less 
able to accept target analogues. This hypothesis is consistent with the binding properties 
of our aptamers and suggests that aptamer CE-3.13 adopts a folded structure, either as a 
free molecule or in the bound state that is more rigid than the other aptamers that we 
tested. 
Mutagenesis data supports the prediction that aptamer CE-3.13 represents a 
complex solution to the chemical problem of how a DNA molecule would fold itself into 
a tertiary structure with a ligand binding site that is capable of selectively recognizing the 
alkaline protein histone H4. Single-nucleotide revertants constructed for each of the four 
genetic mutations that occur in the region of the sequence that defines the predicted 
secondary structure maintain high affinity binding but abate specificity. Furthermore, 
specificity is not restored when the C23G and G41A revertants are modified with 
compensatory mutations that change the G19:G23 and C34:A41 mismatches to C19:G23 
and T34:A41 base pairs, respectively. Since positions 23 and 41 occur in adjoining 
helices of the predicted secondary structure, successful restoration of specificity would 
have meant that these mutations were selected to maintain two contiguous helices in the 
aptamer structure. However, since neither compensatory mutation allowed the aptamer to 
recover specificity, it is reasonable to assume that both mutations play a greater role in 
aptamer folding. This prediction is supported by our footprinting analysis (Figure S2.4). 
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A second interesting observation to emerge from our results was that a limited 
sampling of aptamers (in this case six aptamers were examined after directed evolution) 
yielded a DNA molecule that was capable of achieving high specificity. One 
interpretation that is consistent with our results is that the counter selection method used 
to isolate these aptamers provided access to complex structures that are capable of folding 
into rigid shapes with well-defined ligand binding sites, but that these structures are still 
somewhat rare when compared to simpler structures that continue to dominate the pool. 
This scenario agrees with the long held belief that in vitro selection tends to produce the 
simplest solutions to a given biochemical problem. This hypothesis is evident from our 
previous selection for histone-binding aptamers, which selected for protein-binding 
affinity only and produced molecules with high affinity but low specificity. In contrast, 
the current selection strategy, which included a direct selection for specificity allowed us 
to favor the enrichment of aptamers with specific ligand binding properties by removing 
many of the simpler solutions from the pool. We speculate that our previous selection 
contained aptamers that were capable of high specificity but these molecules were so rare 
that random sampling of the selection output could not identify them. 
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2.5 Conclusion. 
In summary, we provide evidence that nucleic acid aptamers can be evolved by in 
vitro selection to fold into shapes that recognize alkaline proteins with high specificity. 
Because these aptamers are rare relative to simpler molecules that bind with high affinity 
but low specificity, their isolation requires strong counter selection measures that deplete 
the pool of low specificity binders. In the broader context of aptamer binding, these 
results suggest that aptamers could be used as affinity reagents to target a wide range of 
human proteins, including structures whose surfaces are dominated by an abundance of 
positive charge. 
 
2.6 Experimental Design 
2.6.1 General. DNA oligonucleotides were purchased from Integrated DNA 
Technologies and purified by denaturing polyacrylamide gel electrophoresis. Histone 
peptides (H4, GGKGLGKGGAKRHRK; H3, ARTKQTARKSTGGKA; H2 A, 
GKQGGKARAKAKTRS; H2 B, SAPAPKKGSKKAVTK) were purchased from Sigma–
Aldrich in >95 % purity. Histone peptides with a C-terminal biotin residue (H4, 
GGKGLGKGGAKRHRK-Biotin; H3, ARTKQTARKSTGGKAGK-Biotin; H2 A, 
GKQGGKARAKAKTRSGK-Biotin; H2B, SAPAPKKGSKKAVTK-Biotin) were 
purchased from New England Peptide in >95 % purity. Histone proteins H2 A, H2 B, H3, 
and H4 were purchased from New England BioLabs. The 100-mer DNA library 
containing a random region of 50 nucleotides flanked on both sides with constant PCR 
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primer binding sites, and a second generation DNA library based on clone 4.33 were 
purchased from the Keck Facility at Yale University. 
2.6.2 In vitro selection.  For each round of selection, the DNA library was 
amplified by PCR using a 6-carboxyfluorescein (6-FAM)-labeled forward primer (5′-
FAM-GAG CTA CGT ACG AGG ATC CGG TGA G-3′) and a biotin-labeled reverse 
primer (5′-Biotin-GGA CCT GGG GCC GAA GCT TAG CAG T-3′). The pool was 
made single-stranded by immobilizing the dsDNA onto streptavidin-coated agarose beads 
and eluting the top strand with NaOH (0.15 M). The single-stranded library was 
neutralized, ethanol precipitated, and folded by heating to 95 ℃ for 5 min and cooling on 
ice for 10 min in selection buffer (NaCl (100 mM), MgCl2 (5 mM), HEPES (10 mM), pH 
7.5). The DNA library was incubated for 1 h at 24 ℃ with histone peptides H2A, H2B 
and H3 derivatized with a C-terminal biotin residue. After 1 h, the solution was passed 
through a column of streptavidin-coated agarose beads. The unbound fraction was 
collected, concentrated by ethanol precipitation, and refolded. The DNA pool was 
incubated with the histone H4 peptide for 1 h at 24 ℃, and histone H4 aptamers were 
isolated by separating the bound molecules from the unbound library by capillary 
electrophoresis. After four rounds of in vitro selection and amplification, the library was 
cloned and sequenced to examine the diversity of molecules that remained in the pool. 
2.6.3 Capillary electrophoresis. Capillary electrophoresis was performed on 
Beckman ProteomeLab PA 800 Protein Characterization System. Prior to use, the glass 
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capillary (0.1 mm inner diameter, total length=60 cm) was rinsed with water and 
equilibrated with selection buffer. A small portion (70 nL) of the library/peptide mixture 
was injected onto the capillary using pressure injection (0.5 psi for 5 s) and 
electrophoresis was performed under a constant voltage of 15 kV at 20℃ for 35 min. 
Laser-induced fluorescence (LIF) was used to monitor the separation of 6-FAM-labeled 
DNA (λex=488 nm; λem=520 nm). Five injections were performed for each round of in 
vitro selection. 
2.6.4 Directed evolution. Directed evolution was performed to optimize clone 
4.33 (5′-CAC GAC TCT CAC CTC ATA GC tgg tgg ggt tcc cgg gag ggc ggc tac ggg ttc 
cgt aat cag att tgt gt CTG GTT CTG TAG ACG GCT TG-3′). A degenerate DNA library 
was constructed by solid-phase DNA synthesis using mixtures of phosphoramidite 
monomers that allowed for 15 % mutagenesis to occur at each nucleotide position in the 
aptamer sequence. Lower case bases in clone 4.33 denote a region of the sequence that 
contains 85 % of the wild-type nucleotide and 5 % of each of the other three bases. New 
PCR primers were used to avoid possible contamination with the first-generation library. 
The DNA library was amplified by PCR and made single-stranded by denaturing on 
streptavidin-coated agarose beads. The pool of single-stranded DNA was split into two 
parts, and two separate selections were carried out in parallel. The first selection was 
performed as described above with the exception that only histone H3 peptide was used 
in the negative selection step. All other steps were the same, including the solution-phase 
separation of the bound aptamers by capillary electrophoresis. The second selection was 
perform in a similar manner with the exception that the positive selection step was 
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performed by capturing the portion of DNA that remained bound to histone H4 peptide 
on a streptavidin-coated magnetic beads, washing to remove the unbound molecules, and 
amplifying the bound material by PCR. After three rounds of in vitro selection and 
amplification, both libraries were cloned and sequenced to examine the diversity of 
molecules that remained in the pool. 
2.6.5 DNA sequencing and analysis. DNA sequences present in the output of 
each selection were amplified by PCR and cloned into a pJET DNA cloning vector 
(Fermentas). The vectors were transformed into E. coli TOP10 competent cells and 
grown on ampicillin agar plates at 37 ℃ with an overnight incubation. Individual 
colonies were randomly picked and checked by colony PCR to ensure that the vector 
contained the insert. Positive clones were grown in liquid media, mini-prepped, and 
sequenced at the ASU Sequencing Facility. The predicted secondary structures were 
determined using the computer program mFold.
[23]
 
2.6.6 Dot blot binding assay. DNA aptamers (150 pmol) were labeled with 
32
P 
by incubating with [γ-32P] ATP and T4 polynucleotide kinase for 1 h at 37 ℃. The [32P]-
labeled aptamers were desalted on a sephadex G-25 column, diluted with selection buffer 
and folded by heating at 95 ℃ for 5 min and cooling on ice for 10 min. The purified 
aptamers were then divided into 12 tubes and incubated for 1 h at 24 ℃ with the histone 
protein poised at concentrations that span the expected Kd (typically 0.1–100 nM). After 
1 h, the solutions were placed into a vacuum minifold dot blot apparatus and the bound 
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aptamers were partitioned away from the free DNA by passing the solution through a 
layer of nitrocellulose and nylon membranes. 
[24] 
To reduce any nonspecific binding and 
retention of the free DNA, the nitrocellulose membrane was presoaked for 10 min in 
KOH (0.4 M) and rinsed with water until the pH returned to neutral. Prior to analysis, 
both membranes were equilibrated in selection buffer for 30 min at 4 ℃ followed by 
passing selection buffer through the wells with vacuum. Samples were then loaded into 
the dot blot minifold and vacuum was applied to separate the bound aptamer from the 
unbound DNA. Aptamers that are bound to histone become captured on the surface of the 
nitrocellulose membrane (top layer), while unbound DNA passes through the 
nitrocellulose layer and becomes captured on the nylon membrane (bottom layer). The 
wells were then washed with selection buffer, dried, and the amount of radioactivity 
present on both membranes was determined by phosphorimaging. The protein-bound 
aptamer fraction and protein concentration were used to determine the Kd using the 
following equation: 
  
     
       
         
            
 
Here Ib and Iu are the intensity of protein-bound aptamer and free aptamer, 
respectively, c1 and c2 are constants. Dissociation constants were calculated using a 
nonlinear least-squares regression analysis performed with the DeltaGraph program. 
2.6.7 Structural probing by hydroxyl radical footprinting. Hydroxyl radical 
footprinting reactions were performed similar to previously described. 
[32] 
Briefly,[
32
P]-5′-
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end labeled aptamer was incubated in high salt conditions in the presence or absence of 
histone proteins and equilibrated for 1 h at room temperature (total volume 10 μL). The 
hydroxyl radical cleavage reaction was prepared by carefully spotting a fresh FeII-EDTA 
solution ((NH4)2Fe(SO4)2 (3 mM), EDTA (6 mM), 1 μL), sodium ascorbate (30 mm, 1 
μL), and 1.8 % hydrogen peroxide (1μL, freshly diluted from a 30 % stock) as three 
separate drops on the wall of the tube. The reaction was initiated by simultaneously 
mixing the three individual reagent drops together and immediately adding this mixture 
to the aptamer solution. The reaction was quenched by addition of stop solution (100 mM 
thiourea, 7 μL) after 1 min of digestion. 
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Figure S2.1. Predicted secondary structures and free energy values (kcal/mol) of 23 
clones isolated after four iterative rounds of in vitro selection and amplification. 
Aptamers were folded under conditions that simulated a salt concentration of 100 mM 
NaCl and 5 mM MgCl2, and a temperature of 25 °C. With the exception of clones 4.32 
and 4.36, which show simple stem-loop structures and clones 4.8, 4.9 and 4.57, which 
have stem-loop motifs modified with a small bulge, most of the clones (18 out of 23) 
adopt more complicated structures with tandem stemloop motifs in their predicted 
secondary structure. Eight representative clones chosen for further analysis are 
highlighted in green. Hanyang Yu contributes to this figure. 
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Figure S2.2. Predicted secondary structures (unstructured region not shown) of clone 
4.33 calculated under simulated low salt (100 mM NaCl, 5 mM MgCl2) and high salt 
(500 mM NaCl,10 mM MgCl2) conditions. When the concentrations of metal ions 
increase, clone 4.33 adopts a third stem-loop motif in its secondary structure. 
 
 
 
 
 
 
 77 
 
 
Figure S2.3. Sequence alignment of the clones generated by directed evolution of clone 
4.33. The sequences are aligned in order of increasing mutations from top to bottom. 
Conserved nucleotides are highlighted in yellow, and semi-conserved bases are 
highlighted in green. 
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Figure S2.4. Footprinting of aptamer CE-3.13 complexed with and without histone 
proteins using hydroxyl radical. The protected region by the H4 protein is denoted by 
bracket on the right side of the H4 lane. Experiment performed by Hanyang Yu 
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Figure S2.5. Dot blot filter binding assay. For each histone protein, the top row is 
nitrocellulose membrane capturing protein-bound aptamer, and the bottom row is nylon 
membrane with free aptamer. Experiment performed by Hanyang Yu 
 
 
 
 
 
 
 
 
 
 
 81 
Chapter 3  
Generating DNA NuPromers from Previously Discovered Peptides 
 
Rui Liu, Bing Jiang, Hanyang Yu and John C. Chaput 
 
 
PUBLISHED: Generating DNA Synbodies from Previously Discovered Peptides, 
ChemBioChem, 2011, 12(12), 1813-1817. 
Adapted with permission from John Wiley and Sons 
Copyright 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
 
 
 
 
 
 
 
 82 
3.1 Contributions 
The following chapter describes a collaborative research project to generate a high 
affinity DNA NuPromer that binds Grb2 protein which mimics the recognition properties 
of natural antibodies from off-the-shelf peptides. Rui Liu designed and constructed series 
of NuPromer constructs and measured their relative binding affinity by surface plasmon 
resonance. Rui Liu compared the binding properties of NuPromer with antibody by 
enzyme-linked immuno sorbent assay and surface plasmon resonance. Hanyang Yu 
examined the ability of NuPromer to discriminate Grb2 from other proteins with 
MALDI-TOF. Bing Jiang validate that NuPromer can identify Grb2 protein by 
immuneprecipitation and western blot analysis. Rui Liu, Dr. Chaput, Bing Jiang and 
Hanyang Yu wrote the manuscript. The result of this work was published on 
ChemBioChem. 
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3.2 Abstract 
We demonstrate how off-the-shelf peptides can be transformed into high affinity 
protein capture reagents that mimic the recognition properties of natural antibodies. The 
designer synthetic antibody amplifies the binding affinity of the individual peptides by 
∼1000-fold to bind Grb2 with a Kd of 2 nM, and functions with high selectivity in 
conventional pull-down assays from HeLa cell lysates. 
 
3.3 Introduction 
Creating protein capture reagents on a proteome-wide scale is a grand challenge 
in molecular medicine. 
[1]
 High quality reagents are critical for elucidating protein 
function, and developing diagnostic and therapeutic agents. Although antibodies remain 
the gold standard, their cumbersome production in animals is expensive, time consuming, 
and can fail for many targets. 
[2]
 Alternative technologies like single-chain antibodies and 
aptamers overcome some of these limitations, but still require many iterative rounds of 
selection and amplification to produce high-quality binders. 
[3]
 Problems such as these 
have created a pressing need for next generation technologies that lend themselves as 
tools to explore the human proteome, but are more efficient and cost-effective to produce 
than existing reagents. Ideal protein capture reagents would be constructed with minimal 
effort from easy-to-assemble building blocks that are readily available and inexpensive. 
[4]
 The most promising reagents would function in assays that already exist for antibodies. 
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Bivalent reagents are attractive candidates for synthetic antibodies because the 
interactions they produce can be much stronger than their corresponding monovalent 
interactions. 
[5]
 This approach has been used to create many protein affinity reagents, 
[6]
 including a recent bivalent peptoid that targets vascular endothelial growth factor 
receptor 2 (VEGFR-2) in vitro and in cells.
 [7] 
Unfortunately, the discovery process used 
to create these reagents has been difficult to scale. Recently, we developed a new type of 
protein affinity reagent called a “nucleic acid-protein polymer (NuPromer) [15]” the 
synthesis of which does not require in vitro selection or challenging synthetic chemistry. 
[8]
 Instead, DNA NuPromers are produced by a process that we refer to as ligand 
interactions by nucleotide conjugates (LINC). LINC uses a short double-stranded DNA 
scaffold to determine the optimal separation distance and angular geometry needed to 
transform two ligands into a single high affinity protein capture reagent. 
[9]
 
In our original demonstration, we relied on peptide microarrays to identify ligands 
that recognize distinct sites on the surface of a desired protein target. 
[8]
 While this 
strategy provided a rapid method of peptide identification, ligands produced in this way 
are limited in their ability to be optimized for higher binding affinity. 
[10]
 Recognizing 
that many disease-associated proteins have peptide ligands that are well-documented and 
thoroughly characterized, we wondered whether such molecules could be used as a 
readily available source of chemical parts to create high quality NuPromers. Here, we 
demonstrate the feasibility of this strategy using previously discovered peptides with 
known affinity to growth factor receptor-bound protein 2 (Grb2) to create an anti-Grb2 
NuPromer. We chose Grb2 because of its importance in growth-factor-mediated cell 
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signaling, 
[11]
 which is involved in numerous cellular responses including pathways that 
contribute to tumor growth and metastasis. 
[12]
 
 
3.4 Result 
3.4.1 Ligand Identification. Two peptides that recognize non-overlapping sites 
on the surface of human Grb2 were identified. The SH2-binding peptide (ASpYVNVSA) 
contains a phosphotyrosine (pY) residue that is essential for high affinity binding, and 
closely mimics the natural Grb2 binding partner, phosphorylated tyrosine kinase, in the 
signal transduction pathway.
[13a]
 This SH2-binding peptide is reported to have a 
dissociation constant (Kd) of 0.5 μm. The second peptide, YEVPPPVPPRRR, which 
selectively binds the N-terminal SH3 domain of Grb2 with a reported Kd of 5 μM, is a 
natural proline-rich ligand. 
[13b]
 The dissociation constants of both Grb2-binding peptides 
were verified by surface plasmon resonance (SPR). The two peptides were found to bind 
Grb2 near their reported literature values; 0.4(±0.1) μM for the SH2-binding peptide and 
7.5(±5.7) μM for the SH3-binding peptide. 
3.4.2 NuPromer Design. We began by creating a focused library of NuPromer 
constructs (SC) based on the two Grb2 peptides. SCs were assembled in both the forward 
and reverse orientations by separately conjugating one peptide to the 5′ end of the sense 
strand and attaching the other peptide to downstream positions on the antisense strand. 
Annealing the two strands together yielded a series of bivalent NuPromers that sampled a 
distance of approximately 1–6 nm on the DNA scaffold (Figure 3.1 A). The forward 
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orientation was arbitrarily defined as the set of NuPromers that contained the SH3-
binding peptide on the sense strand and the SH2-binding peptide at variable positions on 
the antisense strand. By default, the reverse orientation contained the opposite set with 
the two peptides spaced at identical distances but on opposing strands of the DNA helix. 
An SPR T-100 instrument equipped with auto-injection capability was used to 
rapidly screen each SC for affinity to recombinant Grb2. Measurements were made by 
flowing the SCs over a Grb2 sample that was immobilized on a CM5 biosensor chip. 
From this data, a clear trend emerged in which SCs assembled in the forward orientation 
produced higher relative binding responses than those produced in the reverse orientation. 
Close inspection of the NuPromers constructed in the forward orientation revealed that 
NuPromer construct 12 (SC-12) with an estimated separation distance of 4.1 nm, 
produced the highest binding response relative to the other five SCs assembled with that 
orientation (Figure 3.1 B). This is an interesting arrangement for a bivalent affinity 
reagent because it positions the two peptides roughly 180° apart on the DNA helix. Other 
NuPromer constructs, such as SC-9 or SC-15, which narrow or widen the space between 
the two peptides (~3.1 and ~5.1 nm, respectively), have lower binding; this indicates that 
these SCs are suboptimal relative to SC-12. SC-6 showed no detectable binding in three 
independent trials; this suggests that this configuration might produce an intramolecular 
peptide–peptide interaction that precludes Grb2 binding. All of the other SCs examined 
showed intermediate binding to Grb2, indicating that they bind Grb2 less efficiently than 
SC-12. 
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Figure 3. 1. Design and affinity measurement of NuPromer constructs. A) Cartoon 
representation illustrating six SCs screened for affinity to Grb2. SCs were designed to 
spatially separate the SH3-binding peptide and the SH2-binding peptide by 3, 6, 9, 12, 15, 
and 18 bp (nanometer distance given in parenthesis). B) The SCs were assayed for 
relative binding affinity to Grb2 by using SPR. The cartoon image above each bar 
indicates the relative position of each peptide with respect to the longitudinal axis of the 
dsDNA helix. Experiment performed by Rui Liu. 
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3.4.3. Comparing NuPromers to Antibodies. One recurring question that is 
often raised about synthetic antibodies is how well do these reagents compare to 
antibodies? Recognizing the importance that alternative affinity reagents could play in 
large-scale proteomics research, 
[1b]
 we decided to explore this question through a series 
of side-by-side assays that compare the binding properties of SC-12 to a typical 
commercial antibody. Using a standard ELISA-like assay, we found that Ab-4 and H-9, 
two randomly selected antibodies purchased from separate vendors bind Grb2 with Kd 
values of 67(±31) and 45(±16) nm, respectively. In our experience, this level of binding 
is typical for a standard commercial antibody. SC-12 binds to Grb2 with a Kd of 6.9(±0.4) 
nm, which is five- to tenfold stronger than either commercial antibody (Figure 3.2). This 
result is particularly striking when considering the fact that NuPromers represent a class 
of affinity reagents that are structurally much simpler than any protein fold, especially 
one as complex as an immunoglobin. 
To further explore the binding properties of our Grb2 NuPromer, SPR was used to 
measure the kinetic profiles for SC-12 and H-9. The H-9 antibody was chosen for this 
experiment because it binds to Grb2 with higher affinity than the Ab-4 antibody. When 
Grb2 is passed over a surface containing SC-12, an immediate increase in binding 
response is observed and equilibrium is reached within 30s (Figure 3.2). This result is 
indicative of rapid binding between Grb2 and the immobilized SC-12 affinity reagent. In 
contrast, the same assay performed on the H-9 antibody showed a much slower rate of 
binding and equilibrium is not yet reached after 75 s. Analysis of the individual rate 
constants indicates that the on-rate (kon) of SC-12 is more than five-times faster than the 
 90 
on-rate of H-9 (kon=7.3×105 and 1.3×105 m−1 s−1, respectively). In contrast, SC-12 and 
H-9 have similar off-rates (koff=0.0014 and 0.0021 s−1, respectively); this indicates that 
once Grb2 is bound, protein dissociation occurs relatively slowly. Calculation of the 
dissociation constants from the kinetic terms reveals that SC-12 has an approximately 
tenfold higher affinity for Grb2 than H-9 (Kd of 1.9 vs 16.5 nm, respectively), which is 
consistent with the binding results obtained from the ELISA assay. Overall, these results 
are very encouraging as high affinity binding and slow dissociation kinetics represent a 
hallmark of a high quality protein capture reagent. 
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Figure 3.2. Comparison of the binding properties of SC-12 to a standard commercial 
antibody. Dissociation constants for NuPromer SC-12, and antibody H-9 bound to Grb2 
were measured by using an ELISA assay. SC-12 bound Grb2 with a Kd of 6.9 nM, while 
the commercial antibody H-9 bound Grb2 with a Kd of 45 nM. Dissociation constants 
were validated by SPR. SC-12 was found to have an on-rate that is five-times faster than 
the antibody H-9, and both reagents have similar off-rates. This difference in binding 
kinetics results in tighter binding affinity for SC-12 when compared to H-9. Experiment 
performed by Rui Liu 
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In addition to ligand binding affinity, protein specificity is an equally important 
parameter to consider when evaluating the quality of a protein affinity reagent. We, 
therefore, examined the ability of SC-12 to discriminate against other proteins commonly 
found in complex biological mixtures. Using a standard immunoprecipitation assay, SC-
12 was challenged to isolate recombinant Grb2 protein spiked into a fresh solution of 
HeLa cell lysate (Figure 3.3 A). SC-12 immobilized on streptavidin-coated magnetic 
beads was incubated with spiked HeLa cell lysate for 15 min at 4 °C, after which the 
beads were thoroughly washed, and the bound material was eluted with biotin and 
analyzed by MALDI-TOF mass spectrometry (Figure 3.3 B). The resulting spectrum 
shows a clear peak at approximately 26 kDa, which is identical in mass to our pure 
recombinant Grb2 protein standard. Since no other significant peaks were observed with 
a molecular mass above 15 kDa, we conclude that SC-12 functions with high specificity. 
To validate the identity of the Grb2 antigen and determine the efficiency of 
protein capture, a second assay was performed in which immunoprecipitated Grb2 was 
analyzed by Western blot analysis. Solutions of either PBS buffer or crude HeLa cell 
lysate were spiked with 40 to 400 ng of pure recombinant Grb2. Following an 1 h 
incubation at 24 °C, the beads were washed and the bound material was eluted with 0.1 % 
SDS. All of the material present in the eluate was analyzed by Western blot analysis. 
Comparison of the amount of Grb2 recovered from the buffered solutions with the HeLa 
cell lysate demonstrates that SC-12 functions with high efficiency since both gels yielded 
similar amounts of protein and no bands other than Grb2 were observed (Figure 3.3 C). 
By comparing the amount of protein present in each lane to recombinant Grb2 standards 
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on the same gel, we conclude that SC-12 can easily detect approximately 100 ng of Grb2 
in either solution. To ensure that the bands observed in the Western blot corresponded to 
the recombinant Grb2 protein, a third assay was performed on HeLa cell lysate in which 
samples either contained or were missing the Grb2 spike (Figure 3.3 D). Analysis of the 
resulting Western blot demonstrates that Grb2 protein was only detected in solutions that 
contained the recombinant spike; this is consistent with the ability of SC-12 to bind and 
remove Grb2 from a complex mixture. 
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Figure 3.3.  Specificity of SC-12 in HeLa cell lystate. A) NuPromer-coated 
magnetic beads specifically bind and remove Grb2 from HeLa cell lysate. B) Mass 
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spectrum of the eluate recovered from the pull-down assay reveals a single peak that is 
equivalent in mass to pure Grb2. Western blot analysis of the eluate from pull-down 
assays demonstrate efficient removal of Grb2 from buffer and lysate solutions. Bands 
observed in the Western blot correspond to recombinant Grb2. Hangyang Yu contributes 
to this figure.  
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3.5 Conclusion 
In summary, we demonstrate that readily available peptides can be combined 
using the LINC technology to create NuPromers that recapitulate antibody function by 
capturing their cognate antigens in complex biological mixtures. We suggest that the 
simplicity of this process in combination with the quality of the reagent produced make 
LINC an attractive strategy for accelerating the pace of affinity reagent production. 
 
3.6 Experimental Design. 
3.6.1 Materials. DNA oligonucleotides were purchased from the Keck Facility at 
Yale University. Peptides were purchased from GenScript Corporation with 95 % purity. 
Peptides were synthesized with a C-terminal Gly-Ser-Cys linker. Mouse monoclonal anti-
Grb2 antibodies H-9 and Ab-4 were purchased from Santa Cruz Biotechnology and 
Thermo Scientific, respectively. 
3.6.2 NuPromer construction. All NuPromer constructs were designed and 
synthesized as previously described. 
[8] [14]
 In brief, the template strand (5′-dCCCGAA 
ACAACC GCGAGA GGCACG CGCGTA GC-3′), which contained an amine modified 
deoxycytidine residue at position 1, (shown in bold) was separately conjugated to each 
peptide. A series of complementary strands (5′-dGCTACG CGCGTG 
CCTCTCGCGGTT GTTTCG GG-3′), which contained amine modified 
deoxynucleotides (shown in bold) at internal positions that are 3, 6, 9, 12, 15, and 18 
nucleotides (from the 3′ end) were separately conjugated to both peptides. Peptide–
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oligonucleotide conjugates (POCs) were PAGE purified, isolated, and quantified by UV 
absorbance. POCs were annealed in 1×HBS-P buffer (0.01 M HEPES, pH 7.4, 
0.15 M NaCl, 0.005 %, v/v, surfactant P20) supplemented with MgCl2 (5 mM) and heated 
to 55 °C for 5 min and then cooled on ice. 
3.6.3 NuPromer distance screen. Grb2 NuPromer constructs (SCs) were 
screened for relative binding affinity to Grb2 by using a Biacore T-100 SPR instrument. 
Grb2 (0.025 mg/ mL, 8344 response units) was immobilized onto the surface of a CM5 
chip (GE Healthcare) by using the manufacturer′s recommended protocol. NuPromer 
constructs (1 mm) were passed over the Grb2 chip in 1×HBS-P buffer at a flow rate of 30 
mL/ min. The binding responses were measured in triplicate, and all sensograms were 
corrected by background subtraction from the reference cell. 
3.6.4 Affinity determination. The affinity of SC-12 was measured by coating a 
microtiter 96-well plate with streptavidin protein (2 mg /mL in 0.1 M sodium bicarbonate, 
pH 9.8), overnight, at 4 °C in a humidifier. The solution was removed and replaced with 
blocking buffer (100 mL, 2 % BSA in 1×HBS-P, pH 7.4), and incubated for an additional 
1 h at 37 °C in the humidifier. The solution was removed, and the plate was washed three 
times with 1×HBS-P and tapped dry. The biotin-modified Grb2 SC-12 (10 nM) was 
added to the plate in 1×HBS-P buffer supplemented with MgCl2 (5 mM) and incubated 
for 30 min at room temperature. Unbound NuPromer was removed from the well and a 
concentration series of Cy3-labeled Grb2 (100 mL) was incubated with the plate for 1 h 
at 37 °C. The solution was removed, and the plate was washed three times with 1×HBS-P. 
The plate was scanned by using a SpectroMax plate reader for fluorescence (λex=550 nm, 
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λem=570 nm). Assays were conducted in duplicate and the data were corrected by 
background subtraction. The data were plotted and analyzed by using GraphPad Prism 
software. The affinities of anti-Grb2 antibodies H-9 and Ab-4 were determined in the 
same manner with the exception that the antibodies were coated directly onto the 96-well 
plate. 
3.6.5 Kinetic characterization. Kinetic parameters of the SC-12 and the H-9 
antibody were determined by using a Biacore T-100 SPR instrument. Avidin (0.025 
mg /mL, 15 000 response units) was immobilized onto a CM5 chip by using standard 
amine coupling chemistry. SC-12 containing a biotin label at the 3′-end of the template 
strand was added to the chip in 1×HBS-P buffer at a flow-rate of 10 mL/ min1 for 1000 s, 
which resulted in 1400 response units immobilized to the chip. Grb2 protein (250 nM) 
was passed over the chip at a rate of 30 mL/ min for a contact time of 80s, followed by a 
300s dissociation time. The on-rate (kon), off-rate (koff) and the solution dissociation 
constant (Kd) were determined by using a 1:1 binding model in the Biacore software 
package. The solution binding parameters of the H-9 antibody were determined in the 
same manner by immobilizing the antibody directly onto the surface of CM5 chip (1402 
response units). 
3.6.6. Pull-down assay. The streptavidin coated magnetic beads (DynaBeads, 
Invitrogen) were washed three times with of 1×HBS-P buffer (30 mL) supplemented with 
MgCl2 (5 mM). The biotin containing Grb2 SC-12 (150 pmol) was incubated with the 
beads for 15 min at room temperature. The beads were washed, and then incubated with 
HeLa cell lysate (5 mL of A280=15.68 in 1×HBS-P) spiked with Grb2 (220 pmol) for 15 
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min at 4 °C. The beads were washed three times with 1×HBS-P buffer (30 mL), the 
bound proteins were eluted by using excess biotin (1 mm). The elution was lyophilized 
down to 5 mL, and 1 mL was mixed with 3 mL of matrix (sinapic acid saturated, 125 mL 
acetonitrile, 235 mL water, 16 mL trifluoroacetic acid). A negative control was conducted 
in a similar manner by incubating the magnetic beads with HeLa cell lysate spiked with 
Grb2 for 15 min at 4 °C. Mass spectrometry analysis of the pure Grb2 protein, elution 
from the pull-down assay, and the elution from the negative control were performed on a 
Bruker Autoflex III MALDI-TOF mass spectrometer operating in linear delayed-
extraction mode with 19.00 kV full accelerating potential. 
3.6.7. Immunoprecipitation. Biotin-conjugated SC-12 (20 μL, 1 μM) was 
incubated with streptavidin-coupled M-270 Dynabeads (20 μL, Invitrogen) at room 
temperature for 1 h. Grb2 protein was prepared in phosphate buffered saline (PBS; 100 
mM). The NuPromer-coated beads were washed three times with PBS (20 μL) and 
incubated, overnight, with the desired amount of target protein at 4 °C. For the specificity 
detection, serial dilutions of protein were prepared in diluted soluble HeLa cell lysate 
(A280=1.4244). After binding, the beads were washed again three times with PBS (20 μL) 
and heated at 90 °C in SDS (0.1 %, 15 μL) diluted in PBS and 4×LDS loading buffer (5 
μL, Invitrogen) for 10 min. The samples were run on a 4–12 % precast SDS-PAGE gel 
(Invitrogen) at 200 V for 30 min. The proteins were verified by Western blot detection by 
using anti-Grb2 primary antibody (Santa Cruz Biotechnology) and goat anti-mouse-IgG–
HRP secondary antibody (Bethyl Laboratories). 
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Chapter 4 De Novo Evolution of Size-expanded Protein Structure 
 
4.1 Abstract 
It is widely believed that large, complex proteins with biological functions 
evolved from a small number of progenitor folds, yet it is unclear how these primordial 
folds arose and evolved into these complex proteins. Here we address on one aspect of 
the problem, which is the ability to evolve from small protein to large, multi domain 
protein. Starting from a de novo evolved, unique α/β-fold protein scaffold, we employed 
in vitro selection of messenger RNA display to sample a pool of 10
12 
unique sequences 
for the ability to bind ATP. Following seven rounds of selection, we isolated many 
different clones with sequences that are unrelated to each other or anything else in 
existing protein database, and screened for the clones with best biophysical properties. 
Four out of hundreds of clones displayed decent stability and solubility, suggesting that 
we are capable to generate size-expanded proteins from a single primordial template. 
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4.2 Introduction 
Enzymes that exist in nature presumably evolved from pools of random sequences 
during a process through billions of years. But very little is known about how they 
evolved into larger, more complex structure and how they developed their active 
biocatalytic functions. 
[1] 
One possible hypothesis is that multi-domain proteins are 
evolved by duplication, divergence or recombination of single domain proteins 
[2]
, and 
natural proteins that have been evolved into certain structures but lacked biological 
functions represent inefficient starting points for catalyst development because these 
structures are heavily biased by natural selection 
[3] [4]
. Because the paleobiological 
records have long since been erased 
[5] [6]
, synthetic methods that mimic the events 
happened 3 billion years ago when primordial first appeared on earth must be applied to 
understand the evolution of complex enzymes 
[7]
. Here we address this issue by evolving 
a previous selected ATPase DX into larger protein.  
The DX project originated from an attempt in 2001 to ascertain the frequency of 
ATP binding protein in a library containing 80 contiguous random amino acids 
[8]
. 
Starting from 6×10
12
 different sequences, four different families of protein that do not 
share sequence similarity between one another and any existing known protein sequence 
were identified to bind ATP following eight rounds of mRNA display selection with the 
frequency of roughly 1 in 10
11
. One family, family B was further optimized by directed 
evolution for higher binding affinities. After the total number of 18 rounds of selection, 
protein 18-19 binds most strongly, with dissociation constant (Kd) of 100nM against ATP 
at 4℃.  
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But the biophysical characters of the protein selected were hard to determine due 
to the poor solubility of selected protein. Thus another selection was performed under 
increasingly denaturing conditions to improve folding stability with protein 18-19
[9]
. This 
protein displayed a unique zinc-nucleated α/β-fold that is not yet observed by nature [10]. 
Protein 18-19 requires high concentration of free ATP to maintain stable and soluble, 
unlike most naturally occurring proteins. To overcome this limitation, another directed 
evolution was performed and an optimized sequence DX with significantly enhanced 
expression level, thermal stability, solubility and ligand binding affinity was obtained 
[11]
.  
One interesting thing being discovered is that when the DX protein was 
crystallized with 1 equivalent of ATP, it mediates the hydrolysis of ATP to ADP despite 
that the protein was original selected only for ATP binding 
[12]
. Unlike natural ATPase, 
the ATP binding site in DX is zinc independent and displays an unusual bent 
conformation which is stabilized in place by a key bridging water molecule.  
Enzymes are biological catalysts that accelerate the rate as well as specificity of 
different reactions significantly 
[28]
. Most of enzymes are proteins, but there are also 
nucleic acid enzymes which are referred to as ribozyme or deoxyribozyme 
[32]
. The 
reaction that enzymes catalyze varies from the metabolism of protein to synthesis of 
DNA. Like other catalyst, enzymes work by lowering the activation energy of the 
reaction, and thus increase the velocity of reaction dramatically. They don’t, however, 
change the equilibrium of the reaction 
[29]
. They usually display a high specificity to their 
substrates and the reaction that they catalyzed. The activity of enzyme can be impacted 
by many factors, such as temperature, ion concentration and existence of inhibitors 
[30]
. 
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During a reaction, the transition state is a particular configuration which is defined 
as the state corresponding to the highest potential energy along the reaction coordinates 
[31]
. Typically, enzymes stabilize the transition state to lower the required energy to 
complete the transition. The favored-model for enzyme-substrate binding is the induced 
fit model 
[32]
.It proposed that since enzymes have rather flexible structure, the initial 
interaction between the substrate and enzyme is not very strong, but the active site will be 
continuously reshaped as the substrate interacts with the enzyme. There are two types of 
substrate binding: uniform binding, in which enzymes bind strongly with substrate, and 
differential binding, in which enzymes bind strongly with the transition state, and they 
both share the similar induced fit model. Differential binding is employed by most of the 
enzymes, during which the interaction between the transition state and enzyme keeps 
changing until the full interaction between them is stable and strong. Typically, the 
kinetics of single substrate catalyzing enzyme is fit into the Michaelis-Menten kinetics 
[33]
.  
In nature, the hydrolysis of ATP is normally coupled with other reactions driven 
by the energy generated from dephosphorylation process (ATPase) or modification of 
phosphorylation to other proteins (kinase) 
[34]
. Natural ATPases are typically integral 
membrane molecules that associated with transferring ions against their gradients. While  
natural enzymes bind ATP in a metal-dependent linear conformation that buried ATP in a 
hydrophobic deft, DX only binds ATP in a bent geometry through water molecules as the 
‘bridge’ without the help of metal ions.  
Despite the stability, solubility, affinity and ability to hydrolyze ATP of this man-
made protein, there are a few interesting questions remained. The first thing is that DX is 
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a relatively small protein (about 9600 Dalton) compared with nature enzymes. Secondly, 
the catalytic activity is much lower than the enzymes existing in nature. So it is for us to 
further explore whether we can generate larger protein with more than one domain and 
whether man-made proteins can display biocatalytic functions similar to natural-existing 
enzymes as previously stated. 
There are mainly two types of approach for enzyme evolution: modifying the 
existing enzyme 
[35]
 or introducing functions into existing scaffold 
[36]
. The previous 
approach would be relatively easy, but the modification is limited by the chemistry of 
known enzyme. The latter approach is more difficult with novel chemistry. However, the 
efficiency of enzymes generated this way is often limited. By combining the DX protein 
and random region, we can take advantage of both the existing function of DX and the 
novel chemistry of the random region. Also, the random region might be able to create a 
binding pocket that mimics the binding pocket natural ATPase to bury the whole ATP 
molecule in the pocket. 
The first step of evolving a multi-domain functional protein is to select proteins 
with good biophysical characteristics. In the paper we generated a random library with 
DX protein and 80mer additional amino acids to the C terminus and selected for proteins 
that bind ATP using mRNA display 
[13] [14]
. Although both phage display 
[15]
 and 
ribosome display 
[16]
 has been applied to improve the structural properties of proteins, 
neither of them has the complexity in the library as well as a stable genotype-phenotype 
linkage for denaturing conditions to improve the stringency of selection 
[9]
. The output of 
selection was analyzed for their stability and solubility with different assays.  
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4.3 Result 
4.3.1 Library design and construction. We began by generating the random 
library for our selection, which is too long to synthesize directly. To generated 80mer 
random sequence, two previously pre-selected 20mer libraries were treated with BbsI and 
BbvI digestion enzymes, respectively. These two enzyme digestion sites have 
complementary sticky ends, and when the two digested sticky ends conjugate together, 
the recognition site would be cut off and the newly formed double stranded DNA would 
not be recognized by any of these enzymes and thus would not be digested. The 
conjugation of two 20mer libraries formed a 40mer library, and two 40mer libraries were 
also cloned with these two sites respectively and formed a random 80mer library. For the 
DX protein part, instead of using the full length DX sequence, an output from the directed 
evolution that generated DX protein 
[11]
, which contains roughly 1% mutation rate, was 
chosen as the starting sequence to create more diversity for the selection. The C terminus 
of protein, which does not fit into protein structure, was chopped off. The DX library and 
random library were treated with BbsI and BbvI, respectively. After enzyme digestion of 
these two sequences, DX was ligated with 80mer random library with T4 ligase to form 
the DX80 DNA library that is ready for mRNA display selection (Figure 4.1). The DX80 
library contains T7 promoter and TMV translation enhancer at the 5’ end and the out of 
frame stop codon and cross linking region for crosslinking with psoralen at the 3’ end. 
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Figure 4.1 The construction of DX80 DNA library. Two random libraries were 
treated with BbsI and BbvI restriction enzyme, respectively. Ligation of two enzyme 
digested 20mer library formed a 40mer library and the same treatment of 40mer library 
formed a 80mer random library. DX mutagenetic library from previous selection and the 
80 mer library were also digested with BbsI and BbvI, respectively, and two libraries 
ligated into DX80 DNA library after digestion. Andrew Larsen contributes to the 
construction of random library. 
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The DNA library was transcribed into mRNA, PAGE purified and photo ligated 
to a DNA-puromycin linker by psoralen phtocrosslinking reagent to conjugate the 
puromycin linker to the 3’ end of the mRNA [17]. The whole template was translated in 
vitro with rabbit reticulocyte lysate to produce a library with random protein region 
(phenotype) covalently linked to the mRNA genotype. The mRNA-protein fusion was 
purified with oligo dT cellulose column and the mRNA portion was reverse transcribed 
into mRNA-cDNA double stranded formation to avoid the unwanted enrichment of RNA 
aptamers (Figure 4.2). 
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Figure 4.2 Selection of DX80 protein that binds ATP. The double stranded DNA 
library was transcribed into mRNA and linked with psoralen-puromycin linker, which 
covalently linked the translation product with mRNA forming the mRNA-protein fusion 
library after in vitro translation. After reverse transcription, the mRNA-cDNA-protein 
fusion library was incubated with C8 linked ATP agarose column and the bound 
sequences were eluted with 10mM ATP and PCR amplified for the next round of 
selection. Seven rounds of selection were applied and increasing concentration of 
guanidine hydrochloride was added to the selection step to increase the stringency of 
selection. 
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4.3.2 Evolution of DX80 protein by mRNA display. To optimize the enabled 
structure of protein without compromising the protein function, a previously used 
strategy to increase the stringency of the selection with both structural and functional 
constrains was built into the selection step 
[9] [11]
. The sequences with better folds would 
be enriched by incubating the mRNA-protein fusion with the ATP-agarose resin in the 
presence of guanidine hydrochloride (GuHCl), which has the ability to denature partially 
folded unstable proteins. The concentration of GuHCl increased from 0M to 2M through 
seven rounds of selection to ensure that less than 20% of the input survived through each 
round of selection. By inactivating the pool prior to every round of selection and eluting 
under equilibrium conditions with 10mM free ATP, ATP binding proteins that remained 
folded and functional under denaturing conditions were enriched through the selection 
process. Guanidine hydrochloride was removed by NAP columns prior to PCR 
amplification at the beginning of next round. Enrichment of proteins desired were 
examined through Fluorescence-activated cell sorting (FACS), which will be stated in the 
next paragraph.  
 
4.3.3 Identification of Soluble and Stable Protein through Fluorescence 
Intensity Assay. To screen for proteins that are stable and soluble, output of each round 
of selection was cloned into a GFP reporting vector (Figure 4.3a). The more soluble 
expressed protein is, the better C terminus GFP reporter protein fusion will express, thus 
high fluorescence value indicates a highly soluble protein 
[18] [19]
. The fluorescence level 
increased through seven rounds of selection, which indicates the enrichment of soluble 
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protein through the selection (Figure 4.3b). To select individual sequences with high 
stability and solubility, output of round seven was cloned into GFP vector, expressed in 
BL21 cells and measured by fluorescence reader with excitation wavelength of 485 nm 
and emission wavelength of 515 nm. 18 reproducible clones from 90 clones were 
sequenced and 12 sequences out of 18 have intact ORFs with no stop codons within the 
sequence. For comparison, 51 clones were picked randomly from the output of round 
seven for sequencing and 23 sequences out of 51 have full length ORFs with no stop 
codons. Interestingly, all 35 sequences show no sequence similarity in the random 80mer 
library region. There are a few mutations that appear more commonly than the others, but 
in general there is no consensus part for these sequences, no matter how they were 
selected originally (Supplement Figure 1). 
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Figure 4.3 GFP assay to screen for soluble and stable protein. a) DX80 protein is 
cloned into the vector and expressed as the DX80-GFP fusion protein b) representative 
FACS result from round0, 3, 5 and 7. DX library serves as a positive control and 
significant increasing in number of cells with higher fluorescence value can be observed. 
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4.3.4 Protein Expression and Purification. To investigate the stability and 
solubility of these selected clones, all 35 clones were cloned into a pMAL plasmid and 
expressed protein in BL21 strain of E. coli with N terminus fusion of maltose binding 
protein (MBP) with a thrombin-cleavage linker separating the MBP and DX80 protein. 
Proteins were purified from crude lysated with amylose affinity resin and quantified with 
UV spectroscopy. The concentration of fusion protein expressed and purified from each 
clones were further compared using SDS gel electrophoresis for multiple times. Eight 
clones out of 35 clones that presented high expression level and high concentration after 
purification reproducibly were chosen for further studies (Figure 4.4a).  
To make sure that free ATP binding proteins can display the same solubility 
without the assistance of MBP protein, the MBP fusion proteins were treated with 
thrombin proteolysis at room temperature for three days to be cleaved into their 
respective proteins. The mixture was centrifuged to separated insoluble aggregation from 
free soluble protein and analyzed by SDS gel electrophoresis to detect soluble free ATP 
proteins. All four proteins remained to be soluble at different levels, but they all failed to 
display very high level of soluble ATP binding protein after thrombin treatment (Figure 
4.4b). All selected clones were measured multiple times with this assay (data not shown) 
and the four best clones out of hundreds initial clones are clone 7.5, 7.16, 7.19 and 7.67 
and they were further analyzed. 
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Figure 4.4 Expression and purification of selected clones. a) Expression and 
purification of MBP-DX80 fusion protein. All these clones were expressed in BL21 strain 
of E.Coli cells, purified by amylose binding column and analyzed by SDS gel 
electrophoresis. The gels shown only represent typical results. All these clones were 
expressed and purified for multiple times. b) Thrombin cleavage assay of different clones. 
MBP-DX80 fusion proteins were treated with thrombin to be cleaved into respective 
proteins. The mixture was centrifuged and supernatant was analyzed by gel. None of 
these four proteins shown remain soluble at a high level after three days cleavage under 
room temperature.  
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4.3.5 Modification of Selected Sequences. To improve the selected proteins, the 
first attempt was to cut off the C terminus of protein. DX has previously demonstrated 
that not the entire protein was required for the structure and ATP binding, so the 
constructs with C terminus deletion were built for attempt to eliminate deleterious regions 
that might nucleate aggregation. The N-terminus was kept as it was part of the α-helical 
region of DX structure and previous deletion analysis of 18-19 led to loss of functions. 
Four, eight, twelve, sixteen and twenty amino acids were deleted for each sequence 
(Figure 4.5a) and each truncated version was tested for solubility of free protein with 
thrombin cleavage assay. Four deletions did not lead to any improvement in solubility in 
all four clones while 12 amino acid truncations led to increasing of soluble protein in all 
four clones. 8 and 16 deletions increased solubility for most of the clones but not all four. 
Interestingly, 20 amino acids deletions produced very little protein for all the clones, 
which indicates that part of the functional sequence might have been truncated (Figure 
4.5b). 
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Figure 4.5 C-terminus deletion analysis of Clone 7.16 and 7.67. a) Deletion of 
different number of amino acids from C terminus. b) Clone 7.16 and 7.67 with different 
number of truncations were assayed for solubility using SDS gel electrophoresis both 
with and without the treatment of thrombin. 
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In the original DX protein that was crystallized, a FLAG tag was attached to the 
protein 
[11]
. Also, cysteines in the random region were mutated into serines with the sulfur 
being replaced by oxygen 
[20]
, thus prevents the formation of non-native inter or intra 
disulfide bond that can potentially lead to aggregation 
[21]
. We constructed the clones with 
FLAG tag and cysteine to serine mutations, respectively, expressed them in BL21 cells 
and treated the fusion protein with thrombin overnight. The FLAG tag attached protein 
has a higher expression level and purity while the mutated protein clone, with slightly 
higher protein expression level, has a much lower solubility both after the amylose 
column purification and overnight thrombin cleavage, which indicates that the mutated 
cysteines might have important functions in maintaining the structure of the protein. 
(Figure S4.2) One possibility is that these cysteines might form native disulfide bond, 
which is essential to the structure. 
 
4.3.6 Purification with ATP column. To ensure that the proteins being selected 
actually binds with ATP, we attempted to purify the free ATP binding protein with ATP 
agarose column. After overnight treatment of thrombin, the free protein was bound to an 
ATP agarose column. The unbound proteins in the mixture were washed away and free 
proteins were eluted with buffer containing 10mM ATP. Decent amount of free DX80 
protein can be recovered after purification, indicating that the protein has ATP binding 
properties (Figure 4.6). 
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Figure 4.6 Purification of ATP binding protein with ATP agarose column. After 
protein expression, it was first purified by amylose column and cleaved by thrombin 
overnight into free ATP binding proteins. The solution was centrifuged and the 
supernatant was incubated with C-8 agarose column for 1hour under room temperature. 
After the flow through passed by, the column was washed for 5 times with 1mL binding 
buffer every time and eluted with 10mM ATP five times. The flowthrough and elutions 
were analyzed by SDS gel electrophoresis. 
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4.4 Conclusion and Discussion 
Using mRNA display, we were able to select a multiple domain protein with 
decent stability and solubility. Previous approaches of evolving multi-domain protein 
mostly based on proteins that already exist 
[22] [23] [24] [25]
, so the protein we generated is 
the first ever unnatural multi-domain protein which was evolved from completely random 
sequences. The diversity of mRNA display makes it possible to find a rare sequence in 
random library 
[26]
.  
For a relatively large library, the chances that a problem occurs during selection 
process are larger. The efficiency of PCR amplification; transcription and reverse 
transcription would be lower; unwanted products are more likely to appear; and less 
fusion library would be recovered after each round of selection. To overcome these 
problems, before the actual selection process, a mock selection that did not include the 
selection (binding-elution) step was applied to the library to test different conditions and 
the one that worked best was further applied to the selection. 
Comparing with traditional cell expressing assay, GFP screening might not be the 
best approach for screening soluble clones. One reason is that E.coli cells are too small 
for FACS to discriminate them. Also, the small volume of 96 well plates limits the 
growth and expression of cells. Despite the pre-selection procedure with GFP assay, two 
out of 12 sequences from GFP assay performed well while two out of 23 sequences that 
were randomly picked performed equally well. 
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After this selection, the four best clones with flag tag and 12 amino acids 
deletions at C terminus were mutated into doped library using mutagenic PCR 
[27]
 and 
evolved with another six rounds of selection. Two clones survived the directed evolution 
(Figure S4.3). Further analysis of the selection output indicates that the biophysical 
properties improved through the selection, and size exclusion assay indicates that they are 
mostly monomer proteins (Figure S4.4). Other biophysical analysis, such as circular 
dichroism spectroscopy and nuclear magnetic resonance will be applied and hopefully a 
X-ray crystallization structure can soon be achieved for this protein. 
 
4.5 Experimental Design 
4.5.1 Construction of mRNA-Protein Fusion Library. The DX-random library 
was generated from an output library of DX protein selection and a library with 20 amino 
acids random region. The 20 amino acids library contains the forward primer (5’TTC 
TAA TAC GAC TCA CTA TAG GGA CAA TTA CTA TTT ACA ATT ACA 3’) with 
information necessary for in vitro transcription and translation, and the reverse primer (5’ 
ATA GCC GGT GCT ACC GCT CAG GGC CTG ATA 3’) incorporated with a unique 
three amino acid signature (AKG), two out-of-frame stop codons and a psoralen-DNA-
puromycin linker. PCR amplified 20mer random library was cleaved with BbvI and BbsI 
restriction cites and ligated to form random library with 40 random amino acids. The 80 
mer random library was constructed with the same method. Then the DX library was 
digested with BbvI and ligated with BbsI treated random library with 80 random amino 
acids. The ligated DX-80 library was PCR amplified, cleaned with PCR cleanup kit 
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(Qiagen) and transcripted with T7 RRNA polymerase. The mRNA library was purified 
by 8% denature PAGE, electroeluted and ethanol precipitated. Purified RNA was 
photochemically ligated to a psoralen-DNA-puromycin linker (5’-psoralen-
TAGCCGGTG-(PEG9)2-dA15CC-puromycin; Glen Research, underlined positions 
denote 2’-methoxy nucleosides), by irradiating for 15 minutes at 366nm in a 96 well plate 
with 50 μL reaction per well. The crosslinked material was purified with Hi purifiy RNA 
isolation column (Roche) and translated in vitro by incubating for 1 hour at 30℃ in 
200μL rabbit reticulocyte lysated (Promega) with translation buffer [100mM KCl, 
0.5mM Mg(OAc)2, amino acids mix] and [
35
S-methionine] (PerkinElmer). In situ fusion 
formation was stabilized by the addition of KCl and MgCl2 to final concentration of 
615.4mM and 76.9mM respectively while incubated at room temperature for 15 minutes. 
mRNA-protein fusions were purified by oligo-dT column (New England Biolabs) and 
reverse transcripted by Superscript II RT (Invitrogen) with the RT-primer (5’-d-T15AA 
CCG CTC AGC TTG GCC TG-3’) to prevent RNA  from folding into secondary 
structure during the process of selection. 
4.5.2 Selection of ATP Binding Proteins. mRNA-protein fusions were incubated 
with C-8 linked ATP agarose beads (Sigma) in selection buffer [20mM HEPES, 5mM 
MgCl2 400mM KCI, 0.1% Triton-X and 10mM freshly made DTT] supplemented with 
0-2 M GuHCl for 2 hours at 4℃ in a 5mL disposable column (Biorad). The column was 
drained, washed with 10 column volumes of selection buffer and eluted stepwise with 10 
minutes incubations with 0.25 mL aliquots of selection buffer supplemented with 10mM 
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ATP. Elution fractions were monitored by the radioactivity using Scinallation counter 
and each fractions were combined, NAP-5 (GE) exchanged into water and PCR amplified 
for the next round of selection. Following seven rounds o f selection, the amplified DNA 
was cloned into a pJET vector (Fermentas) and sequenced. 
4.5.3 Fluorescence Intensity Assay for Protein Stability and Solubility. The 
DX80 protein library after seven rounds of selection was inserted into folding reporting 
GFP vector (pET-28a(+)-GFP) with Nco I and BamH I restriction cites. Plasmid DNA 
was transformed into chemically competent E.Coli XLI blue cells (In House), and then 
subcloned into E.coli BL21 strain for GFP expression. Individual clones were selected 
and PCR verified. Bacteria were grown in LB medium with kanamycin at 37℃ for 3 
hours to an A600 of 0.5 and induced with 1mM IPTG for 3 hours in 96 well plates. The 
A600 values were first monitored with the plate reader, and then the fluorescence intensity 
values were obtained with 485 nm as excitation wavelength and 515nm as emission 
wavelength. The intensity value was normalized by dividing the fluorescence read with 
A600 value and subtracts the background. The clones with higheset fluorescent intensity 
were sequenced for further characterization.  
4.5.4 Protein Expression and Purification. The DX80 clones selected from GFP 
assay was inserted into MBP expression vectors (pMAL) with BamH I and Hind III 
cutting sites. Plasmid DNA was transformed into chemically competent E.Coli XLI blue 
cells (In House), PCR verified and sequenced. Plasmid DNA was subcloned into E.coli 
BL21 strain for protein expression. Bacteria were grown in LB medium with kanamycin 
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to an A600 of 0.6 to 0.8 and induced with 1mM IPTG for 3 hours. Bacteria cells were 
harvested by centrifugation, re-suspended in 1mL of lysate buffer [100mM Na2HPO4, 
250mM NaCl, 1mg/mL lysozyme, protease inhibitor, pH 8.5] and incubated at 37℃ for 
30 minutes. Then the cells were lysated by sonication and clarified by centrifuging and 
filtration through 0.22μm filter unit (Millipore). MBP fusion proteins were bound to 
amylose column (New England Biolabs) with amylose binding buffer [100mM Na2HPO4, 
250mM NaCl, pH 8.5] and eluted with amylose binding buffer supplied with 10mM 
maltose. Concentrations of different elutions were determined through A280 and the yield 
is about 100mg per liter.  
4.5.6 Thrombin Cleavage Assay for Protein Solubility. MBP-DX80 fusion 
proteins (~1mg/mL) were incubated overnight at room temperature with thrombin 
(0.05mg/mL) to cleave the fusion proteins into individual proteins. The relative amount 
of free DX80 and MBP proteins remaining in the solution were monitored by 
centrifuging the reaction mixture and analyzing an aliquot (15μL) of the supernatant on a 
4%-20% gradient SDS PAGE gel (Invitrogen). Comparing the band intensity of each 
different clone provided a direct assessment of relative solubility.  
4.5.7 ATP column purification of protein. MBP-DX 80 protein (about 1mg/ml) 
was incubated at room temperature with thrombin (0.05mg/ml). The mixture solution was 
centrifuged after about 18 hours and supernatant was incubated with C-8 linked ATP 
agarose beads (Sigma) in selection buffer [20mM HEPES, 5mM MgCl2 400mM KCI, 0.1% 
Triton-X and 10mM freshly made DTT, pH=7.5] on a 5mL disposable column (Biorad) 
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for 1 hour. The column was drained while the flow through was collected; washed with 
5mL selection buffer and eluted stepwise with 10 minutes incubation 6 times with 0.1mL 
aliquots of elution buffer [selection buffer supplied with 10mM ATP]. Each flow through, 
wash and elutions were then analyzed by 4%-20% gradient SDS PAGE gel (invitrogen). 
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Figure S4.1 Sequence alignment of 35 clones. Some mutations occurred more 
often than the others in the DX region and there is no consensus region in the random 
80mer region. 
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Figure S4.2 Expression, amylose purification and thrombin cleavage assay of different 
variants of clone 7.67-16. Both FLAG tag and cysteine to serine mutations increase the 
expression level, while only FLAG tag fusion protein maintained the same solubility and 
improved the purity of the free DX80 protein. Most of the protein failed to remain soluble 
after cysteine to serine mutations. 
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Figure S4.3. Directed evolution of four best clones. The four best clones, 7.5, 7.16, 7.19 
and 7.67 were mutated through mutagenetic PCR and distributed equally to form the 
library for directed evolution. After six rounds of selection, only clone 7.5 and 7.19 
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survived the selection pressure, which indicates that they are better clones compared with 
the other two.  Experiment performed by Matthew Dunn. 
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Figure S4.4 Size exclusion chromatography of clone 7.19 Mbp fusion protein before (a) 
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and after directed evolution (b). The portion of monomeric protein increased significantly 
after directed evolution. Experiment performed by Will Selleck. 
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Chapter 5 Summary and Perspective 
 
5.1 Summary and Perspective of Aptamer Selection 
5.1.1 Selection strategy and buffer condition of aptamers. The negative-
positive selection scheme is extremely useful in aptamer selection. It can be applied to 
any selection which target is similar in charge or shape with an off-target.  Electrostatic 
attraction is the strongest non-covalent bond, following by hydrogen bond; and both 
forces contributes to the interaction between histones and DNA. Taking in account of 
these factors, it is extremely hard to select aptamers that are specific to histone proteins. 
Our result proves that we can successfully eliminate unspecific binders with this strategy. 
If the selected aptamer is not as high-quality as expected, we can improve it by directed 
evolution while increase the stringency of the selection step further by decrease the off-
target/pool ration and increase target/pool ratio.  
All four core histone proteins have very similar structures, N-terminus tail 
peptides containing many basic residues and they are all highly conserved through the 
selection. Although H3 and H4 interact with each other to form the heterotetramer for the 
core octamer, there is no special similarity between their N-terminus tail peptide. Despite 
that, H3 protein is the histone protein that is the most difficult to discriminate from H4 
protein. Gonzalez and co-workers evolved an aptamer to Leishmania infantum histone 
proteins H3 
[1]
. Although it has a low affinity, the specific is still quite poor. So it would 
be interesting to evolve an aptamer that binds with H3 tail peptide with high specificity.  
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By comparing the binding motif and binding pattern of H4 and H3 aptamers, we can 
learn how the aptamers recognize these two proteins and probably why it is hard for 
aptamers to discriminate these two tail peptides. 
 In the original paper, we increased the specificity by increasing the concentration 
of metal ions in the buffer to stabilize the tertiary structure of the aptamer and satisfy the 
competing charges on the protein surface. But our original selection is carried out under a 
low salt condition. So if the same high salt condition is applied to the selection, would it 
stabilize the potential binders, or would it create undesired bias in the selection? One 
technique issue of high-salt condition is that during the capillary electrophoresis step, 
high concentration of salt might cause the blocking of the extremely small capillarity.  
Nevertheless, if we indeed can carry selection under this condition, it would be really 
interesting to compare the output of these two selections. But it is very unlikely that the 
same aptamers can be generated from the two selections, as unlike conventional SELEX, 
the output of CE-SELEX normally displays no sequence similarities. Even if the selection 
is carried under the exact same conditions twice, the output would very likely be totally 
different. So the comparison of the output is mainly focus on their binding affinity and 
specificity as well as the binding site.  
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Figure 5.1 Selection Scheme of aptamer that recognize a phosphorylation on H3 tail 
peptide. The pool will first go through a negative selection step where sequences will be 
incubated with H3 tail peptide and those that bind unspecifically will be washed away. 
The positive selection step will employ the capillary electrophoresis and bound fraction 
will be amplified via PCR. Theoretically, aptamers with high affinity and specificity can 
be generated after four rounds of selection. 
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5.1.2 Aptamers that recognize post translational modifications. As previously 
stated, post translational modifications (PTMs) of histones regulates many different 
biological processes 
[2]
. Since aptamers could serve as a potential alternate with high 
affinity and specificity, yet we still lack evidences to prove that this approach can be 
applied to all different types of PTMs. So as the first step, we can evolve aptamers that 
bind with various types of PTMs on different histone tail peptides, such as H4K20Me3 
and H3S10P, both of which play important roles relate with cancer 
[3]
 (Figure 5.1).  The 
affinity of selected aptamers can be measured by surface plasma resonance and dot blot 
with peptide and protein, respectively 
[4]
. Specificity can be determined by measuring the 
dissociation constant against non-modified version of peptide and protein and 
modification on a different position. If aptamers with high affinity and specificity can be 
successfully evolved with various types of PTMs, we can state that aptamers can serve as 
a useful ligand for discriminate post-translational modifications of histones.  
 
5.2 Summary and Perspective of Protein Selection 
5.2.1 Library determination of DX80 selection. Before we selected the DX80 
protein, we constructed three different types of libraries: DX20, DX40 and DX80; each 
library contains 20, 40 and 80 random amino acids, respectively. DX80 is most likely to 
create a new domain, and it is long enough to possibly form a new binding pocket for 
ATP, which can potentially serve as the catalyzing pocket for enzyme selection. But 
larger random region makes it more difficult for the whole sequence to fold, as the free 
energy required to fold would be larger and the frequency of well-folded protein would 
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be smaller. On the other hand, DX20 is most likely to form a stable protein that maintains 
the function of DX and the selection process would be the easiest, but 20mer region 
might not be capable of forming a new domain, and it may not have enough length to 
construct a new binding pocket for the ATP binding site.  So we decided to take the hard 
way and use DX80 as our starting library. Our data suggested that we successfully 
evolved a multi-domain protein with DX80. 
5.2.2 Further characterization of selected clones. Further tests of biophysical 
properties would be applied to the best clone. The stability of DX80 can be further 
analyzed. The denaturing curve of guanidine hydrochloride (GuHCl) and the thermal 
denaturing curve would suggest the stability of DX80 under different denaturing 
conditions. For the guanidine hydrochloride assay, the free energy of folding is 
determined by monitoring the shift in tryptophan fluorescence with or without ATP in 
increasing concentration of GuHCl. The folding fraction of protein is plotted with 
increasing concentration of GuHCl. For the thermal stability, the temperature at which 
half of the protein is denatured while the other half remains folded is determined by 
monitoring the change in circular dichroism (CD) at 210nm. Various conditions can be 
applied to CD for comparison, such as in the presence and absence of GuHCl or ATP. 
Different clones from the directed evolution can also be measured with both assays to 
determine the best clone 
[5]
.  
The tertiary structure of DX80 can be investigated by NMR. The one-dimensional 
1
H-NMR would indicate different regions in the protein and possible hydrogen bond 
interaction in certain parts of the protein, while the two-dimensional 
1
H
15
N-NMR 
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heteronuclear single-quantum coherence (HSQC) experiment would reveal the interaction 
between 
1
H and 
15N atoms and it is the ‘golden standard’ to determine how stable the 
protein is folded 
[6]
. The HSQC indicates the correlation between the nitrogen and amide 
proton and almost each amide can yield a peak in the HSQC spectra with a few 
exceptional. The 
15
N labeled protein is prepared from minimal media expression of the 
E.Coli cell, and comparison between the original DX and DX80 would help us study how 
the random region change the structure of the protein, whether it is still well-folded, and 
how the binding motif might change. Interestingly, before directed evolution, we were 
not able to express the DX80 7.19 (which is the best clone) with minimal media while a 
significant amount of protein can be produced afterwards, suggesting that the directed 
evolution did improve the stability and solubility of these clones. After that, we can 
perform the complete structure analysis with crystallization 
[7] 
, which would provide a 
distinct vision of how the DX80 comparing with DX. 
Since our goal is to generate a well-folded, multi-domain protein and mimic the 
possible way in nature to evolve large functional protein rather than selecting a protein 
that can bind with ATP, we didn’t use the affinity of DX80 as a factor to select the best 
clones, but it would still be really interesting to measure how these best clones interact 
with ATP. The dissociation constant can be measured by equilibrium ultrafiltration where 
trace amount of γ-[32P]-ATP is incubated with series concentrations of the DX80 protein 
spanning the Kd. To determine the possible binding mechanism of DX80 and ATP, one 
straightforward experiment to do would be measuring the affinity of DX80 against ATP 
as well as ADP, AMP and GTP 
[8]
. It can not only prove that our protein can bind with 
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ATP with decent affinity and specificity, but also indicate how the DX80 binds with ATP. 
The Kd of ATP analogues can be measured by competitive assay where the bound 
32
P-
ATP is replaced by increasing concentration of the competitors. Comparison of the 
affinity and specificity with the original 18-19 protein, DX and DX80 would suggest how 
the random region influences the binding of ATP.  
Furthermore, we can test if DX80 still remains the ATP hydrolysis capability by 
thin layer chromatography (TLC). The α-[32P]-ATP is incubated with DX80 and the 
disappearance of ATP and formation of ADP can be monitored through TLC. At this 
point, our goal is not to generate an enzyme with high biocatalytic function, so result that 
indicates if DX80 can or cannot hydrolysis ATP (i.e. can the ADP be generate) would be 
enough for this step. But further enzyme kinetics measurement can be applied once we 
successfully evolve an enzyme.  
5.2.3 Revolution of unnatural enzymes.  To evolve an enzyme, we can either 
employ the output of previous DX80 selection as the starting point or the random DX80 
library. The output already went through several rounds of stringent selection, most of the 
library sequences should be well-folded or at least partially-folded and it takes away 
some of the selection pressure. But the previous selection was designed to bind ATP, and 
the C8 linker ATP agarose was employed for the binding. This ATP agarose form may 
not give the protein enough space to form a full pocket that can cover the ATP 
completely. So the bias that is already created by the previous selection would become 
problematic during the selection of ATP hydrolysis, in nature form of which ATP is fully 
covered by the protein. If the random library is employed as the starting point, this 
 145 
selection pressure is enormous as the library needs to fold into a stable and soluble 
structure first, and then catalyze the hydrolysis of ATP. But the enzyme can be created 
from a total random sequence and there is no bias in the sequence itself. It would be 
interesting (although it would be huge amount of work then) to carry two different 
selections with these two libraries together in parallel under the exact same conditions, 
and compare the recovery fraction from each round and the output sequences.  
We will employ a strategy that is developed for evolving ribozymes that function 
with metal cofactor for the enzyme selection
 [9]
.  The starting library will be first 
incubated with γ-phosphate ATP agarose. The unbound molecules will be washed off, 
and functionally molecules that can cleave themselves from the column can be eluted 
with cofactor containing buffer since all the natural ATP-dependent enzymes have one or 
more cofactor binding site (Figure 5.2a). The process will be monitored with 
35
S-labeled 
protein. After the selection, the kinetic of selected enzymes can be tested by TLC with 
increasing concentration of substrate. The product information can be plotted as the 
function of concentration of substrate and fit to the Michaelis-Menten equations. The 
parameters for catalyze can be compared with natural kinase. 
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Figure 5.2 Selection scheme of DX80 enzyme. a). The mRNA-cDNA-protein fusion 
library will first be incubated with ATP column and the unbound fusions will be washed 
off. The seqeucens that can cleave themselves from the γ-phosphate linked ATP agarose 
with metal cofactor will be amplified. b) The fusion library will be mixed with reaction 
system containing metal cofactor, ATP-fluorophore and phosphatase in a cell like oil-
water emulsion. If the enzyme can cleave multiple ATP-fluorophore into 
phosphorfluorophore, which will be turned into fluorophore by phosphatase, the emulsion 
will be selected by FACS due to its high fluorescence value. 
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To further improve the selected enzyme to catalyze multiple turnover reactions, 
the efficiency can be optimized by in vitro compartmentalization (IVC) 
[10]
 (Figure 5.2b). 
The genotype and phenotype are first linked together through mRNA-display method to 
minimize the competition from free ATP for transcription. The mRNA-protein fusion 
will be mixed with ATP-fluorophores in oil-water emulsions, with one droplet containing 
one fusion molecule and several ATP-fluorophore molecules. Once the ATP-fluorophore 
is catalyzed into ADP and phosphate-fluorophore, the phosphates enzyme which also 
exists in the reaction mixture would hydrolyze the phosphate-fluorophore into phosphate 
and HO-fluorophore. The droplet can be separated by flow cytometry by detecting the 
free fluorophore. After several rounds of selection, the best clones will be sequenced for 
further analysis. The selected enzymes will also be tested for their biophysical properties 
and crystallized for their structures. 
As previously stated, protein evolution not only generates reagent with certain 
functions, but also provides a vision about how the functional proteins that exist in nature 
arose in the first place. By the previous mentioned approach, we aim to address another 
aspect of the fundamental question: how the progenitors evolved into enzymes with 
robust function in nature? In the previous approach, we have already proved that multi-
domain protein can indeed be evolved from single domain and partially folded protein, 
and we successfully mimicked this natural process by generating a multi-domain protein 
from random library. All the further studies are based on the improvement and full 
analysis of the evolved protein. So the next step would be taking the protein further: from 
the structure to the function. By evolving an enzyme that shares the similar function with 
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natural enzyme while have a completely unnatural folding and binding motif, we can 
address some fundamental questions in evolution.  
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Center Inc., ("CCC�s Billing and Payment terms and conditions"), at the time 
that you opened your RightsLink account (these are available at any time at 
http://myaccount.copyright.com). 
 
Terms and Conditions 
1. The materials you have requested permission to reproduce (the 
"Materials") are protected by copyright.  
2. You are hereby granted a personal, non-exclusive, non-sublicensable, 
non-transferable, worldwide, limited license to reproduce the Materials for the 
purpose specified in the licensing process. This license is for a one-time use 
only with a maximum distribution equal to the number that you identified in 
the licensing process. Any form of republication granted by this license must 
be completed within two years of the date of the grant of this license (although 
copies prepared before may be distributed thereafter). The Materials shall not 
be used in any other manner or for any other purpose. Permission is granted 
subject to an appropriate acknowledgement given to the author, title of the 
material/book/journal and the publisher. You shall also duplicate the copyright 
notice that appears in the Wiley publication in your use of the Material. 
Permission is also granted on the understanding that nowhere in the text is a 
previously published source acknowledged for all or part of this Material. Any 
third party material is expressly excluded from this permission.  
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3. With respect to the Materials, all rights are reserved. Except as 
expressly granted by the terms of the license, no part of the Materials may be 
copied, modified, adapted (except for minor reformatting required by the new 
Publication), translated, reproduced, transferred or distributed, in any form or 
by any means, and no derivative works may be made based on the Materials 
without the prior permission of the respective copyright owner. You may not 
alter, remove or suppress in any manner any copyright, trademark or other 
notices displayed by the Materials. You may not license, rent, sell, loan, lease, 
pledge, offer as security, transfer or assign the Materials, or any of the rights 
granted to you hereunder to any other person.  
4. The Materials and all of the intellectual property rights therein shall at 
all times remain the exclusive property of John Wiley & Sons Inc or one of its 
related companies (WILEY) or their respective licensors, and your interest 
therein is only that of having possession of and the right to reproduce the 
Materials pursuant to Section 2 herein during the continuance of this 
Agreement. You agree that you own no right, title or interest in or to the 
Materials or any of the intellectual property rights therein. You shall have no 
rights hereunder other than the license as provided for above in Section 2. No 
right, license or interest to any trademark, trade name, service mark or other 
branding ("Marks") of WILEY or its licensors is granted hereunder, and you 
agree that you shall not assert any such right, license or interest with respect 
thereto.  
5. NEITHER WILEY NOR ITS LICENSORS MAKES ANY 
WARRANTY OR REPRESENTATION OF ANY KIND TO YOU OR ANY 
THIRD PARTY, EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT 
TO THE MATERIALS OR THE ACCURACY OF ANY INFORMATION 
CONTAINED IN THE MATERIALS, INCLUDING, WITHOUT 
LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY, 
ACCURACY, SATISFACTORY QUALITY, FITNESS FOR A 
PARTICULAR PURPOSE, USABILITY, INTEGRATION OR NON-
INFRINGEMENT AND ALL SUCH WARRANTIES ARE HEREBY 
EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED BY YOU.  
6. WILEY shall have the right to terminate this Agreement immediately 
upon breach of this Agreement by you. 
7. You shall indemnify, defend and hold harmless WILEY, its Licensors 
and their respective directors, officers, agents and employees, from and against 
any actual or threatened claims, demands, causes of action or proceedings 
arising from any breach of this Agreement by you.  
8. IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE 
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TO YOU OR ANY OTHER PARTY OR ANY OTHER PERSON OR 
ENTITY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, 
INDIRECT, EXEMPLARY OR PUNITIVE DAMAGES, HOWEVER 
CAUSED, ARISING OUT OF OR IN CONNECTION WITH THE 
DOWNLOADING, PROVISIONING, VIEWING OR USE OF THE 
MATERIALS REGARDLESS OF THE FORM OF ACTION, WHETHER 
FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT, 
NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, 
WITHOUT LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, 
DATA, FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS OF THIRD 
PARTIES), AND WHETHER OR NOT THE PARTY HAS BEEN ADVISED 
OF THE POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION SHALL 
APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE 
OF ANY LIMITED REMEDY PROVIDED HEREIN.  
9. Should any provision of this Agreement be held by a court of competent 
jurisdiction to be illegal, invalid, or unenforceable, that provision shall be 
deemed amended to achieve as nearly as possible the same economic effect as 
the original provision, and the legality, validity and enforceability of the 
remaining provisions of this Agreement shall not be affected or impaired 
thereby.  
10. The failure of either party to enforce any term or condition of this 
Agreement shall not constitute a waiver of either party's right to enforce each 
and every term and condition of this Agreement. No breach under this 
agreement shall be deemed waived or excused by either party unless such 
waiver or consent is in writing signed by the party granting such waiver or 
consent. The waiver by or consent of a party to a breach of any provision of 
this Agreement shall not operate or be construed as a waiver of or consent to 
any other or subsequent breach by such other party.  
11. This Agreement may not be assigned (including by operation of law or 
otherwise) by you without WILEY's prior written consent.  
12. Any fee required for this permission shall be non-refundable after 
thirty (30) days from receipt 
13. These terms and conditions together with CCC�s Billing and 
Payment terms and conditions (which are incorporated herein) form the entire 
agreement between you and WILEY concerning this licensing transaction and 
(in the absence of fraud) supersedes all prior agreements and representations of 
the parties, oral or written. This Agreement may not be amended except in 
writing signed by both parties. This Agreement shall be binding upon and inure 
to the benefit of the parties' successors, legal representatives, and authorized 
 177 
assigns.  
14. In the event of any conflict between your obligations established by 
these terms and conditions and those established by CCC�s Billing and 
Payment terms and conditions, these terms and conditions shall prevail.  
15. WILEY expressly reserves all rights not specifically granted in the 
combination of (i) the license details provided by you and accepted in the 
course of this licensing transaction, (ii) these terms and conditions and (iii) 
CCC�s Billing and Payment terms and conditions.  
16. This Agreement will be void if the Type of Use, Format, Circulation, 
or Requestor Type was misrepresented during the licensing process.  
17. This Agreement shall be governed by and construed in accordance 
with the laws of the State of New York, USA, without regards to such state�s 
conflict of law rules. Any legal action, suit or proceeding arising out of or 
relating to these Terms and Conditions or the breach thereof shall be instituted 
in a court of competent jurisdiction in New York County in the State of New 
York in the United States of America and each party hereby consents and 
submits to the personal jurisdiction of such court, waives any objection to 
venue in such court and consents to service of process by registered or certified 
mail, return receipt requested, at the last known address of such party.  
Wiley Open Access Terms and Conditions  
Wiley publishes Open Access articles in both its Wiley Open Access 
Journals program [http://www.wileyopenaccess.com/view/index.html] and as 
Online Open articles in its subscription journals. The majority of Wiley Open 
Access Journals have adopted the Creative Commons Attribution License (CC 
BY) which permits the unrestricted use, distribution, reproduction, adaptation 
and commercial exploitation of the article in any medium. No permission is 
required to use the article in this way provided that the article is properly cited 
and other license terms are observed. A small number of Wiley Open Access 
journals have retained the Creative Commons Attribution Non Commercial 
License (CC BY-NC), which permits use, distribution and reproduction in any 
medium, provided the original work is properly cited and is not used for 
commercial purposes. 
Online Open articles � Authors selecting Online Open are, unless 
particular exceptions apply, offered a choice of Creative Commons licenses. 
They may therefore select from the CC BY, the CC BY-NC and the 
Attribution-NoDerivatives (CC BY-NC-ND). The CC BY-NC-ND is more 
restrictive than the CC BY-NC as it does not permit adaptations or 
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modifications without rights holder consent. 
Wiley Open Access articles are protected by copyright and are posted to 
repositories and websites in accordance with the terms of the applicable 
Creative Commons license referenced on the article. At the time of deposit, 
Wiley Open Access articles include all changes made during peer review, 
copyediting, and publishing. Repositories and websites that host the article are 
responsible for incorporating any publisher-supplied amendments or 
retractions issued subsequently. 
Wiley Open Access articles are also available without charge on Wiley's 
publishing platform, Wiley Online Library or any successor sites. 
Conditions applicable to all Wiley Open Access articles: 
 The authors' moral rights must not be compromised. These rights include 
the right of "paternity" (also known as "attribution" - the right for the author to 
be identified as such) and "integrity" (the right for the author not to have the 
work altered in such a way that the author's reputation or integrity may be 
damaged).  
 Where content in the article is identified as belonging to a third party, it 
is the obligation of the user to ensure that any reuse complies with the 
copyright policies of the owner of that content.  
 If article content is copied, downloaded or otherwise reused for research 
and other purposes as permitted, a link to the appropriate bibliographic citation 
(authors, journal, article title, volume, issue, page numbers, DOI and the link to 
the definitive published version on Wiley Online Library) should be 
maintained. Copyright notices and disclaimers must not be deleted. 
� Creative Commons licenses are copyright licenses and do not confer any 
other rights, including but not limited to trademark or patent rights.  
 Any translations, for which a prior translation agreement with Wiley has 
not been agreed, must prominently display the statement: "This is an unofficial 
translation of an article that appeared in a Wiley publication. The publisher has 
not endorsed this translation."  
Conditions applicable to non-commercial licenses (CC BY-NC and CC 
BY-NC-ND) 
For non-commercial and non-promotional purposes individual non-
commercial users may access, download, copy, display and redistribute to 
colleagues Wiley Open Access articles. In addition, articles adopting the CC 
BY-NC may be adapted, translated, and text- and data-mined subject to the 
conditions above. 
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Use by commercial "for-profit" organizations  
Use of non-commercial Wiley Open Access articles for commercial, 
promotional, or marketing purposes requires further explicit permission from 
Wiley and will be subject to a fee. Commercial purposes include:  
o Copying or downloading of articles, or linking to such articles for further 
redistribution, sale or licensing;  
o Copying, downloading or posting by a site or service that incorporates 
advertising with such content;  
o The inclusion or incorporation of article content in other works or 
services (other than normal quotations with an appropriate citation) that is then 
available for sale or licensing, for a fee (for example, a compilation produced 
for marketing purposes, inclusion in a sales pack)  
o Use of article content (other than normal quotations with appropriate 
citation) by for-profit organizations for promotional purposes  
o Linking to article content in e-mails redistributed for promotional, 
marketing or educational purposes;  
o Use for the purposes of monetary reward by means of sale, resale, 
license, loan, transfer or other form of commercial exploitation such as 
marketing products  
o Print reprints of Wiley Open Access articles can be purchased from: 
corporatesales@wiley.com  
The modification or adaptation for any purpose of an article referencing 
the CC BY-NC-ND License requires consent which can be requested from 
RightsLink@wiley.com .  
 
 
Other Terms and Conditions:  
BY CLICKING ON THE "I AGREE..." BOX, YOU ACKNOWLEDGE 
THAT YOU HAVE READ AND FULLY UNDERSTAND EACH OF THE 
SECTIONS OF AND PROVISIONS SET FORTH IN THIS AGREEMENT 
AND THAT YOU ARE IN AGREEMENT WITH AND ARE WILLING TO 
ACCEPT ALL OF YOUR OBLIGATIONS AS SET FORTH IN THIS 
AGREEMENT.  
 
v1.8  
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If you would like to pay for this license now, please remit this license 
along with your payment made payable to "COPYRIGHT CLEARANCE 
CENTER" otherwise you will be invoiced within 48 hours of the license date. 
Payment should be in the form of a check or money order referencing your 
account number and this invoice number RLNK500993230. 
Once you receive your invoice for this order, you may pay your invoice by 
credit card. Please follow instructions provided at that time. 
 
Make Payment To: 
Copyright Clearance Center 
Dept 001 
P.O. Box 843006 
Boston, MA 02284-3006 
 
For suggestions or comments regarding this order, contact RightsLink 
Customer Support: customercare@copyright.com or +1-877-622-5543 (toll 
free in the US) or +1-978-646-2777. 
 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this 
printable license for your reference. No payment is required.  
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